<html>
<?php
/*
This mutation calculator was designed to quickly calculate the change
in information content of a specified variant. It also returns the
number of studies in which this variant has been reported following
our literature review. 
Copyright (C) 2014 Cytognomix Inc.
   
This program is free software; you can redistribute it and/or modify
it under the terms of the GNU General Public License as published by
the Free Software Foundation; either version 3 of the License, or
(at your option) any later version.
   
This program is distributed in the hope that it will be useful,
but WITHOUT ANY WARRANTY; without even the implied warranty of
MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the
GNU General Public License for more details.
   
You should have received a copy of the GNU General Public License
along with this program; if not, write to the Free Software Foundation,
Inc., 51 Franklin Street, Fifth Floor, Boston, MA 02110-1301  USA
*/
?>
<head>
	<title>Reference Table</title>
	<link rel="stylesheet" type="text/css" href="//cdn.datatables.net/1.10.2/css/jquery.dataTables.min.css">
	<link rel="stylesheet" type="text/css" href="//cdn.datatables.net/tabletools/2.2.0/css/dataTables.tableTools.min.css">
	<link rel="stylesheet" type="text/css" href="//cdn.datatables.net/fixedheader/2.1.0/css/dataTables.fixedHeader.min.css">
	<link rel="stylesheet" type="text/css" href="//cdn.datatables.net/colvis/1.1.1/css/dataTables.colVis.css">
	<link rel="stylesheet" type="text/css" href="//cdn.datatables.net/colreorder/1.1.2/css/dataTables.colReorder.css">
	<link rel="stylesheet" type="text/css" href="/css/ref_table_style.css">
	<script type="text/javascript" language="javascript" src="//code.jquery.com/jquery-1.11.1.min.js"></script>
	<script type="text/javascript" language="javascript" src="//cdn.datatables.net/1.10.2/js/jquery.dataTables.min.js"></script>
	<script type="text/javascript" language="javascript" src="//cdn.datatables.net/tabletools/2.2.0/js/dataTables.tableTools.min.js"></script>
	<script type="text/javascript" language="javascript" src="//cdn.datatables.net/fixedheader/2.1.0/js/dataTables.fixedHeader.min.js"></script>
	<script type="text/javascript" language="javascript" src="//cdn.datatables.net/colvis/1.1.1/js/dataTables.colVis.min.js"></script>
	<script type="text/javascript" language="javascript" src="//cdn.datatables.net/colreorder/1.1.2/js/dataTables.colReorder.min.js"></script>
	<script>
	$(document).ready(function(){
    		var table = $('#ref_table').dataTable({
    		allowHTML: true,
			"dom": 'T<"clear">lfrtip',
			"tableTools": {
				"sSwfPath": "//cdn.datatables.net/tabletools/2.2.0/swf/copy_csv_xls_pdf.swf"
			}
		});
		//new $.fn.dataTable.FixedHeader( table );
	
		var colvis = new $.fn.dataTable.ColVis( table );
		$( colvis.button() ).prependTo('#ref_table_wrapper');

		new $.fn.dataTable.ColReorder( table );
		var searchTerm = "<?php echo $_GET['searchterm']; ?>";
		$('.dataTables_filter input').val(searchTerm);
		table.fnFilter(searchTerm);

	});
	</script>
</head>
<body>

<table class="display" cellspacing="0" width="100%" id="ref_table"><thead><tr>
<td>Disease</td>
<td>Prevalence (orpha.net)</td>
<td style="font-style: normal;">Gene</td>
<td>Type of Inheritance</td>
<td>Mutation</td>
<td>Chr</td>
<td>Genomic coordinates</td>
<td>Nature of site affected</td>
<td>Type of site</td>
<td>Predicted effect on site</td>
<td>Ri initial</td>
<td>Ri final</td>
<td>&#916;Ri</td>
<td>SNP ID</td>
<td>Allele frequency</td>
<td>Average Het.</td>
<td>Location of site</td>
<td>Distance from natural</td>
<td>Validation (Y/N)</td>
<td>Validation result</td>
<td>Reference</td>
<td>Identification</td>
</tr></thead><tbody>
<tr><td>Xeroderma pigmentosum-variant</td><td><1 / 1 000 000</td><td>POLH</td><td>autosomal recessive</td><td>NM_006502:c.764+1G>C</td><td>6</td><td>43568829</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>-0.5</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Inui H. J Invest Dermatol. 2008;128(8):2055-2068</td><td>donor0G>C </td></tr>
<tr><td>Xeroderma pigmentosum-variant</td><td><1 / 1 000 000</td><td>POLH</td><td>autosomal recessive</td><td>NM_006502:c.490G>T</td><td>6</td><td>43555226</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>2.1</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Nonsense</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Inui H. J Invest Dermatol. 2008;128(8):2055-2068</td><td>donor-1G>T </td></tr>
<tr><td>Xeroderma pigmentosum-variant</td><td><1 / 1 000 000</td><td>POLH</td><td>autosomal recessive</td><td>NM_006502:c.658A>G</td><td>6</td><td>43565600</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.8</td><td>6.8</td><td>-1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>Y</td><td>Low transcript levels</td><td>Inui H. J Invest Dermatol. 2008;128(8):2055-2068</td><td>donor-3A>G </td></tr>
<tr><td>Schwannomatosis</td><td>N/A</td><td>SMARCB1</td><td>autosomal dominant</td><td>NM_003073:c.92A>T</td><td>22</td><td>24129448</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.4</td><td>1.3</td><td>-2.1</td><td>rs267607072</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>Y</td><td>No cryptic isoform</td><td>Bacci C. Neurogenetics. 2010;11(1):73-80</td><td>donor-2A>T </td></tr>
<tr><td>Hereditary spastic paraplegia (SG31)</td><td>unknown</td><td>REEP1</td><td>autosomal dominant</td><td>NM_022912:c.417+1G>T</td><td>2</td><td>86479079</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.8</td><td>-4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Beetz C. Brain. 2008;131(Pt 4):1078-1086</td><td>donor0G>T </td></tr>
<tr><td>Hereditary spastic paraplegia (SG31)</td><td>unknown</td><td>REEP1</td><td>autosomal dominant</td><td>NM_022912:c.303G>A</td><td>2</td><td>86481817</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.5</td><td>3.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Beetz C. Brain. 2008;131(Pt 4):1078-1086</td><td>donor-1G>A </td></tr>
<tr><td>Hereditary spastic paraplegia (SG31)</td><td>unknown</td><td>REEP1</td><td>autosomal dominant</td><td>NM_022912:c.595G>C</td><td>2</td><td>86459748</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.6</td><td>6.5</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Beetz C. Brain. 2008;131(Pt 4):1078-1086</td><td>donor-1G>C </td></tr>
<tr><td>Iminoglycinuria</td><td>1-9 / 100 000</td><td>SLC36A2</td><td>autosomal recessive</td><td>NM_181776:IVS1+1G>A</td><td>5</td><td>150726857</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.5</td><td>-4.3</td><td>-12.8</td><td>rs371203963</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Broer S. J Clin Invest. 2008;118(12):3881-3892</td><td>donor0G>A </td></tr>
<tr><td>Usher syndrome</td><td>  1-9 / 100 000</td><td>USH2A</td><td>autosomal recessive</td><td> NM_206933:c.3811+3A>T</td><td>1</td><td>216372966</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.9</td><td>4.4</td><td>-4.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>Le Guedard-Mereuze S. Hum Mutat. 2009;30(9):1329-1339</td><td>donor2A>T </td></tr>
<tr><td>Aniridia</td><td>1-9 / 100 000</td><td>PAX6</td><td>autosomal dominant</td><td> NM_000280:IVS12+2T>C</td><td>11</td><td>31814984</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.7</td><td>3.2</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Aggarwal S. Mol Vis. 2011;17:1305-1309</td><td>donor1T>C </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS1+1G>T</td><td>X</td><td>48542375</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.7</td><td>-1.1</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>donor0G>T </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS3+1G>A</td><td>X</td><td>48542375</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>-4.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>Skipping and cryptic</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>donor0G>A </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS11+1G>C</td><td>X</td><td>48547824</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.4</td><td>-1.4</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>donor0G>C </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS9+2T>C</td><td>X</td><td>48546844</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>0.6</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>donor1T>C </td></tr>
<tr><td>Distal myopathy</td><td>unknown - rare</td><td>NEB</td><td>autosomal recessive</td><td>NM_004543:c.2414+5G>A</td><td>2</td><td>152544801</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.3</td><td>4.7</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Lehtokari V. Neuromuscular Disorders. 2011;21(8):556-562.</td><td>donor4G>A </td></tr>
<tr><td>Harlequin ichthyosis</td><td><1 / 1 000 000</td><td>ABCA12</td><td>autosomal recessive</td><td>NM_173076:c.7436G>A</td><td>2</td><td>215807649</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>"Skipping, cryptic and normal"</td><td>Akiyama M. J Invest Dermatol. 2007;127(3):568-573</td><td>donor-1G>A </td></tr>
<tr><td>Harlequin ichthyosis</td><td><1 / 1 000 000</td><td>ABCA12</td><td>autosomal recessive</td><td>NM_173076:c.7436G>A</td><td>2</td><td>215807649</td><td>Cryptic</td><td>DONOR</td><td>Created</td><td>-2.4</td><td>0.2</td><td>2.6</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-4</td><td>Y</td><td>"Skipping, cryptic and normal"</td><td>Akiyama M. J Invest Dermatol. 2007;127(3):568-573</td><td>donor-4G>A </td></tr>
<tr><td>Cysteinosis</td><td>unknown in Mexico - 1/100-200 000 in US</td><td>CTNS</td><td>autosomal recessive</td><td>NM_001031681:c.61+5G>A</td><td>17</td><td>3543566</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.9</td><td>5.4</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Alcantara-Ortigoza MA. Genet Test. 2008;12(3):409-414.</td><td>donor4G>A </td></tr>
<tr><td>Cysteinosis</td><td>unknown in Mexico - 1/100-200 000 in US</td><td>CTNS</td><td>autosomal recessive</td><td>NM_001031681:c.61+5G>A</td><td>17</td><td>3543566</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.9</td><td>5.4</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Alcantara-Ortigoza MA. Genet Test. 2008;12(3):409-414.</td><td>donor4G>A </td></tr>
<tr><td>Glycogen storage disease type III</td><td>unknown</td><td>AGL</td><td>autosomal recessive</td><td>NM_000642:c.293+2T>G</td><td>1</td><td>100327271</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.1</td><td>1.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Aoyama Y. J Hum Genet. 2009;54(11):681-686</td><td>donor1T>G </td></tr>
<tr><td>Glycogen storage disease type III</td><td>unknown</td><td>AGL</td><td>autosomal recessive</td><td>NM_000642:c.958+1G>A</td><td>1</td><td>100336426</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.2</td><td>-4.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Aoyama Y. J Hum Genet. 2009;54(11):681-686</td><td>donor0G>A </td></tr>
<tr><td>Epilepsy</td><td>unknown</td><td>SCN1A</td><td>autosomal dominant (Dravet)</td><td>NM_006920:IVS3+3A>C</td><td>2</td><td>166912918</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.7</td><td>1.9</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Kwong AK. PLoS One. 2012;7(7):e41802</td><td>donor2A>C </td></tr>
<tr><td>Epilepsy</td><td>unknown</td><td>SCN1A</td><td>autosomal dominant (Dravet)</td><td>NM_006920:IVS21+1G>A</td><td>2</td><td>166858981</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.5</td><td>-6.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Kwong AK. PLoS One. 2012;7(7):e41802</td><td>donor0G>A </td></tr>
<tr><td>Leber congenital amaurosis</td><td>1-2/80 000</td><td>CRB1</td><td>autosomal dominant</td><td>NM_201253:c.4005+2T>C</td><td>1</td><td>197411424</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.1</td><td>-1.4</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Li L. PLoS One. 2011;6(5):e19458</td><td>donor1T>C </td></tr>
<tr><td>Skin/heart disease</td><td>N/A</td><td>JUP</td><td>autosomal recessive</td><td>NM_002230:c.468G>A</td><td>17</td><td>39925670</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.2</td><td>0.2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Cabral RM. J Invest Dermatol. 2010;130(6):1543-1550</td><td>donor-1G>A </td></tr>
<tr><td>Bietti crystalline corneoretinal dystrophy</td><td>unknown</td><td>CYP4V2</td><td>autosomal recessive</td><td>NM_207352:IVS2+1G>A</td><td>4</td><td>187115767</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.6</td><td>-4.2</td><td>-12.8</td><td>rs199476182</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Li A. The American Journal of Human Genetics. 2004;74(5):817-826.</td><td>donor0G>A </td></tr>
<tr><td>Albright hereditary osteodystrophy</td><td>unknown</td><td>GNAS</td><td>autosomal dominant</td><td>NM_080425:IVS4+5G>A</td><td>20</td><td>57478645</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.9</td><td>2.3</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Lietman SA.Endocr Pract. 2011;17 Suppl 3:28-32</td><td>donor4G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>PALB2</td><td>N/A</td><td>NM_024675:c.48G>A</td><td>16</td><td>23652431</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.3</td><td>1.3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Catucci I. Genet Med. 2014.</td><td>donor-1G>A </td></tr>
<tr><td>Hyperalphalipoproteinemia</td><td>unknown</td><td>CETP</td><td>co-dominant</td><td>NM_000078:c.1407+2T>C</td><td>16</td><td>57017325</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.9</td><td>0.4</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Cefalu AB. Atherosclerosis. 2009;204(1):202-207</td><td>donor1T>C </td></tr>
<tr><td>X-linked recessive chondrodysplasia punctata</td><td>unknown</td><td>ARSE</td><td>X-linked recessive</td><td>NM_000047:c.430G>A</td><td>X</td><td>2871184</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.9</td><td>2.9</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Cryptic (retention)</td><td>Jeon GW. Ann Clin Lab Sci. 2013;43(1):70-75</td><td>donor-1G>A </td></tr>
<tr><td>Leber congenital amaurosis</td><td>1-9 / 100 000</td><td>MERTK</td><td>autosomal recessive</td><td>NM_006343:c.61+1G>A</td><td>2</td><td>112656374</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.6</td><td>-1.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mackay DS. Mol Vis. 2010;16:369-377</td><td>donor0G>A </td></tr>
<tr><td>Autosomal recessive cone-rod dystrophy</td><td>1/40 000</td><td>PCDH21</td><td>autosomal recessive</td><td>NM_033100:c.1485+2T>G</td><td>10</td><td>85970923</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4</td><td>-4.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Cohen B. Mol Vis. 2012;18:2915-2921</td><td>donor1T>G </td></tr>
<tr><td>Abetalipoproteinemia</td><td>  <1 / 1 000 000</td><td>MTTP</td><td>autosomal recessive</td><td>NM_000253:c.2342+1G>A</td><td>4</td><td>100540256</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.5</td><td>-1.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention)</td><td>Magnolo L. Gene. 2013;512(1):28-34</td><td>donor0G>A </td></tr>
<tr><td>Abetalipoproteinemia</td><td>  <1 / 1 000 000</td><td>MTTP</td><td>autosomal recessive</td><td>NM_000253:c.1236+2T>G</td><td>4</td><td>100521892</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.9</td><td>-1.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Magnolo L. Gene. 2013;512(1):28-34</td><td>donor1T>G </td></tr>
<tr><td>Epidermolysis bullosa </td><td>1-9 / 1 000 000</td><td>COL7A1</td><td>autosomal recessive</td><td>NM_000094:c.6900+1G>A</td><td>3</td><td>48610103</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.5</td><td>-6.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Marchal A.  2011;138(12):A168-A169</td><td>donor0G>A </td></tr>
<tr><td>Congenital nephrogenic diabetes insipidus</td><td>1-9 / 1 000 000</td><td>AQP2</td><td>autosomal recessive</td><td>NM_000486:c.606+1G>A</td><td>12</td><td>50348494</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.1</td><td>-8.7</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Marr N. J Am Soc Nephrol. 2002;13(9):2267-2277</td><td>donor0G>A </td></tr>
<tr><td>Marfan sydrome</td><td>1-5 / 10 000</td><td>FBN1</td><td>autosomal dominant</td><td>NM_000138:c.4747+5G>T</td><td>15</td><td>48760130</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>5.9</td><td>-3.9</td><td>rs193922209</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic (deletion)</td><td>McGrory J. Clin Genet. 1999;55(2):118-121.</td><td>donor4G>T </td></tr>
<tr><td>Ullrich congenital muscular dystrophy</td><td>  1-9 / 1 000 000</td><td>COL6A2</td><td>autosomal recessive</td><td>NM_001849:c.801+3A>C</td><td>21</td><td>47533990</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.5</td><td>5.7</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>Martoni E. Hum Mutat. 2009;30(5):E662-72.</td><td>donor2A>C </td></tr>
<tr><td>Ullrich congenital muscular dystrophy</td><td>  1-9 / 1 000 000</td><td>COL6A2</td><td>autosomal recessive</td><td>NM_001849:c.927+5G>A</td><td>21</td><td>47536322</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.7</td><td>7.2</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Retention</td><td>Martoni E. Hum Mutat. 2009;30(5):E662-72.</td><td>donor4G>A </td></tr>
<tr><td>Colon Cancer</td><td>N/A</td><td>GMDS</td><td>N/A</td><td>NM_001500:c.345+5G>A</td><td>6</td><td>2116000</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.1</td><td>4.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>"Moriwaki K. Gastroenterology. 2009;137(1):188-98, 198.e1-2"</td><td>donor4G>A </td></tr>
<tr><td>Autosomal recessive retinitis pigmentosum</td><td><1/3500</td><td>ABCA4</td><td>autosomal recessive</td><td>NM_000350:IVS14+1G>C</td><td>1</td><td>94526092</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.8</td><td>-1</td><td>-9.8</td><td>rs61749427</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mullins RF. Invest Ophthalmol Vis Sci. 2012;53(4):1883-1894</td><td>donor0G>C </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.904+4A>G</td><td>2</td><td>21257684</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.4</td><td>8.8</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Skipping</td><td>Di Leo E. J Med Genet. 2007;44(3):219-224</td><td>donor3A>G </td></tr>
<tr><td>Lynch syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1731+5G>A</td><td>3</td><td>37083827</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>5.1</td><td>-3.5</td><td>rs267607850</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Naruse H. Fam Cancer. 2009;8(4):509-517</td><td>donor4G>A </td></tr>
<tr><td>Lynch syndrome</td><td>unknown</td><td>MSH2</td><td>autosomal dominant</td><td>NM_000251:c.211+1G>A</td><td>2</td><td>47630542</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.5</td><td>-1.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Naruse H. Fam Cancer. 2009;8(4):509-517</td><td>donor0G>A </td></tr>
<tr><td>Xeroderma pigmentosum variant B</td><td>  <1 / 1 000 000</td><td>ERCC3</td><td>autosomal recessive</td><td>NM_000122:c.471+1G>A</td><td>2</td><td>128050185</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.5</td><td>-7.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Oh KS. Hum Mutat. 2006;27(11):1092-1103</td><td>donor0G>A </td></tr>
<tr><td>Dystrophic epidermolysis bullosa</td><td>1-9 / 100 000</td><td>COL7A1</td><td>autosomal recessive</td><td>NM_000094:c.6899A>G</td><td>3</td><td>48610105</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.5</td><td>4.2</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>Y</td><td>Cryptic</td><td>Oh SW. Br J Dermatol. 2007;157(6):1260-1264.</td><td>donor-2A>G </td></tr>
<tr><td>Dystrophic epidermolysis bullosa</td><td>1-9 / 100 000</td><td>COL7A1</td><td>autosomal recessive</td><td>NM_000094:c.682+1G>A</td><td>3</td><td>48630534</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-7.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Oh SW. Br J Dermatol. 2007;157(6):1260-1264.</td><td>donor0G>A </td></tr>
<tr><td>Chylomicronemia</td><td>1-9 / 1 000 000</td><td>APOA5</td><td>autosomal recessive</td><td>NM_052968:c.49+1G>A</td><td>11</td><td>116662527</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.6</td><td>-3.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Okubo M. Atherosclerosis. 2009;207(1):24-25</td><td>donor0G>A </td></tr>
<tr><td>Idiopathic nephritic syndrome </td><td>10-20% of 16/100 000</td><td>PTPRO</td><td>autosomal recessive</td><td>NM_030667:c.2627+1G>T</td><td>12</td><td>15710458</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.2</td><td>2.4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Ozaltin F. Am J Hum Genet. 2011;89(1):139-147</td><td>donor0G>T </td></tr>
<tr><td>Idiopathic nephritic syndrome </td><td>10-20% of 16/100 000</td><td>PTPRO</td><td>autosomal recessive</td><td>NM_030667:2745+1G>T</td><td>12</td><td>15718563</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9</td><td>1.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Leaky</td><td>Ozaltin F. Am J Hum Genet. 2011;89(1):139-147</td><td>donor0G>T </td></tr>
<tr><td>Hereditary non-polyposis colorectal cancer</td><td>unknown</td><td>MSH2</td><td>autosomal dominant</td><td>NM_000251:c.1661+1G>T</td><td>2</td><td>47693948</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>-4.1</td><td>-7.8</td><td>rs267607969</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Papp J. World J Gastroenterol. 2007;13(19):2727-2732</td><td>donor0G>T </td></tr>
<tr><td>Hemochromatosis type 3</td><td>  <1 / 1 000 000</td><td>TFR2</td><td>autosomal recessive</td><td>NM_003227:c.614+4A>G</td><td>7</td><td>100231035</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.1</td><td>2.5</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Leaky</td><td>Pelucchi S. Haematologica. 2009;94(2):276-279.</td><td>donor3A>G </td></tr>
<tr><td>Hemochromatosis type 3</td><td>  <1 / 1 000 000</td><td>TFR2</td><td>autosomal recessive</td><td>NM_003227:c.614+4A>G</td><td>7</td><td>100231035</td><td>Cryptic</td><td>DONOR</td><td>Created</td><td>1.3</td><td>4.4</td><td>3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Leaky</td><td>Pelucchi S. Haematologica. 2009;94(2):276-279.</td><td>donor4A>G </td></tr>
<tr><td>Papular acantholytic dyskeratosis </td><td>unknown</td><td>ATP2C1</td><td>autosomal dominant</td><td>NM_014382:c.360+2T>A</td><td>3</td><td>130656309</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.7</td><td>4.9</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Leaky</td><td>Pernet C. Br J Dermatol. 2012;167(1):210-212</td><td>donor1T>A </td></tr>
<tr><td>Hidradentitis suppurativa</td><td>>1 / 1000</td><td>NCSTN</td><td>autosomal dominant</td><td>NM_015331:c.996+7G>A</td><td>1</td><td>160322003</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.5</td><td>8.1</td><td>-0.4</td><td>rs202046846</td><td>-</td><td>-</td><td>Intronic</td><td>6</td><td>Y</td><td>Low transcript levels</td><td>Pink AE. J Invest Dermatol. 2012;132(10):2459-2461</td><td>donor6G>A </td></tr>
<tr><td>Autosomal recessive congenital ichthyosis</td><td>1-9 / 1 000 000</td><td>ALOXE3</td><td>autosomal recessive</td><td>NM_021628:c.434G>A</td><td>17</td><td>8018925</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Eckl KM. J Invest Dermatol. 2009;129(6):1421-1428.</td><td>donor-1G>A </td></tr>
<tr><td>Newfoundland with Rod-cone-dystrophy phenotype </td><td>1-9 / 100 000</td><td>RLBP1</td><td>autosomal recessive</td><td>NM_000326:c.141G>A</td><td>15</td><td>89761796</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.4</td><td>7.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Eichers ER. The American Journal of Human Genetics. 2002;70(4):955-964</td><td>donor-1G>A </td></tr>
<tr><td>Newfoundland with Rod-cone-dystrophy phenotype </td><td>1-9 / 100 000</td><td>RLBP1</td><td>autosomal recessive</td><td>NM_000326:c.141+2T>C</td><td>15</td><td>89761794</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.4</td><td>3</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Eichers ER. The American Journal of Human Genetics. 2002;70(4):955-964</td><td>donor1T>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS7+5G>C</td><td>22</td><td>30054258</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.4</td><td>2.5</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>donor4G>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS14+1G>C</td><td>22</td><td>30074313</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.4</td><td>-3.4</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>donor0G>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS14+2T>C</td><td>22</td><td>30074314</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.4</td><td>-1</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>donor1T>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:c.1737G>T</td><td>22</td><td>30077590</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.1</td><td>0.8</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>donor-1G>T </td></tr>
<tr><td>Junctional epiderdermolysis bullosa</td><td>  <1 / 1 000 000</td><td>LAMB3</td><td>autosomal recessive</td><td>NM_000228:c.628G>A</td><td>1</td><td>209806415</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.2</td><td>5.1</td><td>-3.1</td><td>rs121912482</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Pasmooij AM. J Clin Invest. 2007;117(5):1240-1248</td><td>donor-1G>A </td></tr>
<tr><td>Hypertriglyceridemia</td><td>N/A</td><td>APOA5</td><td>autosomal recessive</td><td>NM_052968:c.161+3G>C</td><td>11</td><td>116662299</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.4</td><td>2</td><td>-4.4</td><td>rs372791079</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>Priore Oliva C. Atherosclerosis. 2006;188(1):215-217</td><td>donor2G>C </td></tr>
<tr><td>High cholesterol</td><td>very common</td><td>ABCA1</td><td>multifactorial</td><td>NM_005502:IVS7+6T>C</td><td>9</td><td>107620797</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.2</td><td>8.8</td><td>-1.4</td><td>rs188308962</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>5</td><td>Y</td><td>Cryptic and normal</td><td>Rhyne J. BMC Med Genet. 2009;10:1.</td><td>donor5T>C </td></tr>
<tr><td>Gitelman's syndrome</td><td>1% of Europeans</td><td>SLC12A3</td><td>autosomal recessive</td><td>NM_000339:c.2633+1G>C</td><td>16</td><td>56928555</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-4.2</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Leaky</td><td>Riveira-Munoz E. J Am Soc Nephrol. 2007;18(4):1271-1283</td><td>donor0G>C </td></tr>
<tr><td>Gitelman's syndrome</td><td>1% of Europeans</td><td>SLC12A3</td><td>autosomal recessive</td><td>NM_000339:c.964+1G>T</td><td>16</td><td>56906375</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.6</td><td>-1.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Leaky</td><td>Riveira-Munoz E. J Am Soc Nephrol. 2007;18(4):1271-1283</td><td>donor0G>T </td></tr>
<tr><td>Gitelman's syndrome</td><td>1% of Europeans</td><td>SLC12A3</td><td>autosomal recessive</td><td>NM_000339:c.1567G>A</td><td>16</td><td>56914165</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.7</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Leaky</td><td>Riveira-Munoz E. J Am Soc Nephrol. 2007;18(4):1271-1283</td><td>donor-1G>A </td></tr>
<tr><td>Gitelman's syndrome</td><td>1% of Europeans</td><td>SLC12A3</td><td>autosomal recessive</td><td>NM_000339:c.1925G>A</td><td>16</td><td>56919276</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.9</td><td>5.8</td><td>-3.1</td><td>rs147901432</td><td>0.03</td><td>0.001</td><td>Missense</td><td>-1</td><td>Y</td><td>Retention</td><td>Riveira-Munoz E. J Am Soc Nephrol. 2007;18(4):1271-1283</td><td>donor-1G>A </td></tr>
<tr><td>Catecholaminergic polymorphic ventricular tachycardia (CPVY) </td><td>1/10 000</td><td>CASQ2</td><td>autosomal recessive</td><td>NM_001232:c.939+5G>C</td><td>1</td><td>116247808</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.6</td><td>6.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Roux-Buisson N. Hum Mutat. 2011</td><td>donor4G>C </td></tr>
<tr><td>Catecholaminergic polymorphic ventricular tachycardia (CPVY) </td><td>1/10 000</td><td>CASQ2</td><td>autosomal recessive</td><td>NM_001232:c.737+1G>A</td><td>1</td><td>116269612</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-7.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Roux-Buisson N. Hum Mutat. 2011</td><td>donor0G>A </td></tr>
<tr><td>Catecholaminergic polymorphic ventricular tachycardia (CPVY) </td><td>1/10 000</td><td>CASQ2</td><td>autosomal recessive</td><td>NM_001232:c.1014+1G>A</td><td>1</td><td>116245541</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.9</td><td>-4.9</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Roux-Buisson N. Hum Mutat. 2011</td><td>donor0G>A </td></tr>
<tr><td>X-linked albinism</td><td>1-9 / 1 000 000</td><td>GPR143</td><td>X-linked ressive</td><td>NM_000273:c.658+1G>A</td><td>X</td><td>9714083</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.2</td><td>-3.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fang S.Mol Vis. 2008;14:1974-1982</td><td>donor0G>A </td></tr>
<tr><td>Wolman disease</td><td>1/528 000<sup>7</sup></td><td>LIPA</td><td>autosomal recessive</td><td>NM_000235:c.229+1G>A</td><td>10</td><td>91005432</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>-4.1</td><td>-12.8</td><td>rs201104126</td><td>0.05</td><td>0.001</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fasano T. Mol Genet Metab. 2011</td><td>donor0G>A </td></tr>
<tr><td>Lipoprotein glomerulopathy-like glomerulopathy </td><td>less than 50 reported cases</td><td>APOA5</td><td>autosomal dominant</td><td>NM_052968:IVS2+5G>C</td><td>11</td><td>116662523</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.6</td><td>5.6</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Soran H. J Clin Lipidol. 2010;4(4):310-313.</td><td>donor4G>C </td></tr>
<tr><td>Branchio-oto-renal syndrome </td><td>unknown</td><td>EYA1</td><td>autosonal dominant</td><td>NM_172060:c.867+5G>A</td><td>8</td><td>72183988</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.3</td><td>4.8</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic</td><td>Stockley TL. Am J Med Genet A. 2009;149A(3):322-327</td><td>donor4G>A </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>NM_000084:IVS3+2T>C</td><td>X</td><td>49837245</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.9</td><td>0.4</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Tosetto E.Nephrol Dial Transplant. 2006;21(9):2452-2463</td><td>donor1T>C </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>NM_000084:IVS5+5G>T</td><td>X</td><td>49845378</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Tosetto E.Nephrol Dial Transplant. 2006;21(9):2452-2463</td><td>donor4G>T </td></tr>
<tr><td>Aniridia</td><td>1-9 / 100 000</td><td>PAX6</td><td>autosomal dominant</td><td>NM_001604:c.141+1G>A</td><td>11</td><td>31824251</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.8</td><td>-6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Wang P. Mol Vis. 2006;12:644-648</td><td>donor0G>A </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:c.515C>T</td><td>18</td><td>28909997</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.7</td><td>8.1</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>donor-3C>T </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:c.515C>T</td><td>18</td><td>28909997</td><td>Cryptic</td><td>DONOR</td><td>Created</td><td>1.8</td><td>9.3</td><td>7.5</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-4</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>donor-4C>T </td></tr>
<tr><td>Congenital adrenal hyperplasia</td><td>1-9 / 1 000 000</td><td>CYP21A2</td><td>autosomal recessive</td><td>NM_00500: c.1222G>A</td><td>6</td><td>32008548</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.9</td><td>4.9</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>-</td><td>Concolino P. Clin Endocrinol (Oxf). 2009;71(4):470-476</td><td>donor-1G>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.2657+5G>A </td><td>7</td><td>117242922</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>5.6</td><td>-3.5</td><td>rs80224560</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Leaky</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>donor4G>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.2988+1G>A </td><td>7</td><td>117246808</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.6</td><td>-3.2</td><td>-12.8</td><td>rs75096551</td><td>0.03</td><td>0.001</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>donor0G>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.2988G>A </td><td>7</td><td>117246807</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.6</td><td>6.6</td><td>-3.1</td><td>rs121908797</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>donor-1G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>CAV3</td><td>inherited or sporadic</td><td>NM_033337:IVS1+2T>C</td><td>3</td><td>8775678</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>0.6</td><td>-7.5</td><td>rs116840787</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>C </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DMD</td><td>inherited or sporadic</td><td>NM_004006:IVS5+1G>T</td><td>X</td><td>32841411</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>3.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSC2</td><td>autosomal recessive or dominant</td><td>NM_024422:IVS15+5G>A</td><td>18</td><td>28648855</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSG2</td><td>autosomal recessive or dominant</td><td>NM_001943:IVS5+2T>C</td><td>18</td><td>29101208</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>0</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>C </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSG2</td><td>autosomal recessive or dominant</td><td>NM_001943:IVS6+1G>A</td><td>18</td><td>29102213</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11</td><td>-1.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSP</td><td>autosomal recessive or dominant</td><td>NM_004415:IVS2+5G>A</td><td>6</td><td>7556058</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>1.9</td><td>-3.5</td><td>rs200473206</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DSP</td><td>inherited or sporadic</td><td>NM_004415:IVS15+1G>C</td><td>6</td><td>7572302</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>0.2</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>C </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>LMNA</td><td>inherited or sporadic</td><td>AK295390:IVS7+1G>A</td><td>1</td><td>156106228</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.1</td><td>-5.7</td><td>-12.8</td><td>rs267607552</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS4+5G>C</td><td>11</td><td>47371560</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.8</td><td>4.9</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS6+5G>A</td><td>11</td><td>47369970</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>5.8</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS7+1G>A</td><td>11</td><td>47369407</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>-4.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS7+5G>A</td><td>11</td><td>47369403</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.7</td><td>5.2</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS7+1G>T</td><td>11</td><td>47369407</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>0.9</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS13+1G>C</td><td>11</td><td>47365042</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.3</td><td>-5.5</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS13+1G>T</td><td>11</td><td>47365042</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.3</td><td>-3.5</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS17+1G>A(IVS16)</td><td>11</td><td>47364128</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.3</td><td>-4.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS17+1G>C(IVS16)</td><td>11</td><td>47364128</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.3</td><td>-1.5</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS21+2T>G (IVS20)</td><td>11</td><td>47361200</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4</td><td>-4.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS23+1G>A (IVS22)</td><td>11</td><td>47360070</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.3</td><td>-5.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS23+1G>T  (IVS22)</td><td>11</td><td>47360070</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.3</td><td>-0.5</td><td>-7.8</td><td>rs112738974</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS29+1G>A  (IVS26)</td><td>11</td><td>47355107</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.9</td><td>-6.9</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS29+5G>A  (IVS28)</td><td>11</td><td>47355103</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.9</td><td>2.4</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS31+1G>A (IVS30)</td><td>11</td><td>47354364</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.6</td><td>-9.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS31+1G>T (IVS30)</td><td>11</td><td>47354364</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.6</td><td>-4.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYH7</td><td>inherited or sporadic</td><td>NM_000257:IVS8+1G>A</td><td>14</td><td>23900793</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5</td><td>-7.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYH7</td><td>inherited or sporadic</td><td>NM_000257:IVS8+3G>C</td><td>14</td><td>23900791</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5</td><td>0.6</td><td>-4.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor2G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>PKP2</td><td>inherited or sporadic</td><td>NM_004572:IVS1+1G>A</td><td>12</td><td>33049442</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.5</td><td>-2.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS4+1G>A</td><td>12</td><td>33021860</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.3</td><td>-2.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS5+1G>C</td><td>12</td><td>33003699</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.8</td><td>-5</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>C </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_001005242:IVS10+1G>C</td><td>12</td><td>32955336</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.4</td><td>-1.4</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>C </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_001005242:IVS12+1G>T</td><td>12</td><td>32945577</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>3.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>T </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_001005242:IVS12+1G>A</td><td>12</td><td>32945577</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11</td><td>-1.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.306+4A>G</td><td>3</td><td>37042548</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.6</td><td>7.1</td><td>-2.6</td><td>rs267607733</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Cryptic</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor3A>G </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.588+5G>A</td><td>3</td><td>37053358</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9</td><td>5.5</td><td>-3.5</td><td>rs267607768</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor4G>A </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.677G>A</td><td>3</td><td>37053590</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.8</td><td>2.7</td><td>-3.1</td><td>rs63751711</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-1G>A </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.790+5G>T</td><td>3</td><td>37056040</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>2.1</td><td>-3.9</td><td>rs267607771</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor4G>T </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.882C>T</td><td>3</td><td>37059088</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>5.5</td><td>-1.6</td><td>rs63751707</td><td>-</td><td>-</td><td>Synonymous</td><td>-3</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-3C>T </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.884+4A>G</td><td>3</td><td>37059094</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>4.5</td><td>-2.6</td><td>rs267607777</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor3A>G </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1037A>G</td><td>3</td><td>37061953</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>4.8</td><td>-2.3</td><td>rs63751609</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>Y</td><td>Skipping and cryptic</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-2A>G </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1038G>T</td><td>3</td><td>37061954</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>3.8</td><td>-3.3</td><td>rs63751715</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-1G>T </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1731G>A</td><td>3</td><td>37083822</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>5.5</td><td>-3.1</td><td>rs63751657</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-1G>A </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1731+5G>A</td><td>3</td><td>37083827</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>5.1</td><td>-3.5</td><td>rs267607850</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor4G>A </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.1989G>T </td><td>3</td><td>37090100</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.2</td><td>3.9</td><td>-3.3</td><td>rs63751662</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-1G>T </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MSH2</td><td>autosomal dominant</td><td>NM_000251:c.1660A>T</td><td>2</td><td>47693946</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>1.6</td><td>-2.1</td><td>rs63751656</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>Y</td><td>Skipping and cryptic</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-2A>T </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MSH2</td><td>autosomal dominant</td><td>NM_000251:c.1759G>C</td><td>2</td><td>47698201</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>3.2</td><td>-4</td><td>rs63751140</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor-1G>C </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MSH2</td><td>autosomal dominant</td><td>NM_000251:c.2634+5G>T</td><td>2</td><td>47708015</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.8</td><td>-0.2</td><td>-3.9</td><td>rs267608017</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>donor4G>T </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>   NM_000084:IVS8+1G>T </td><td>X</td><td>49851528</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>3.1</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Tosetto E. Clin Genet. 2009;76(4):413-416.</td><td>donor0G>T </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>    NM_000084:IVS11+1G>T</td><td>X</td><td>49855544</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.9</td><td>1.1</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Tosetto E. Clin Genet. 2009;76(4):413-416.</td><td>donor0G>T </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>   NM_000084:IVS4+4A>G</td><td>X</td><td>49840641</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.5</td><td>2.9</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Tosetto E. Clin Genet. 2009;76(4):413-416.</td><td>donor3A>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5000</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:c.1903+5G>A</td><td>X</td><td>154182162</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>3.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5000</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:c.6115+5G>A</td><td>X</td><td>154130321</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7</td><td>3.5</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>-</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:c.88+5G>C</td><td>X</td><td>138613016</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>0.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Lower transcript levels</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:c.391+5G>A</td><td>X</td><td>138623353</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>7.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Lower transcript levels</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:c.391+2T>C</td><td>X</td><td>138623350</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>3.7</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>-</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+1G>T</td><td>X</td><td>138613012</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>-3.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+3G>C</td><td>X</td><td>138619335</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.1</td><td>2.7</td><td>-4.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Lower transcript levels</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor2G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3+5G>A</td><td>X</td><td>138619550</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4+7A>G</td><td>X</td><td>138623355</td><td>Natural</td><td>DONOR</td><td>Strengthened</td><td>11.1</td><td>11.5</td><td>0.4</td><td>rs6049</td><td>4.18</td><td>0.08</td><td>Intronic</td><td>6</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor6A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4+5G>A</td><td>X</td><td>138623353</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>7.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+5G>C</td><td>X</td><td>138613016</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>0.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+6T>C</td><td>X</td><td>138619338</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>5.7</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor5T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3+5G>C</td><td>X</td><td>138619550</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.6</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+5G>A</td><td>X</td><td>138613016</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>1.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+1G>C</td><td>X</td><td>138613012</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>-5.2</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+1G>T</td><td>X</td><td>138613012</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>-3.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+2T>G</td><td>X</td><td>138613013</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>-3.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1+5G>T</td><td>X</td><td>138613016</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>0.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+1G>A</td><td>X</td><td>138619333</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.1</td><td>-5.7</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+1G>C</td><td>X</td><td>138619333</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.1</td><td>-2.7</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+5G>A</td><td>X</td><td>138619337</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>3.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor4G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2+6T>C</td><td>X</td><td>138619338</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>5.7</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor5T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3+2T>C</td><td>X</td><td>138619547</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>0.1</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3+2T>G</td><td>X</td><td>138619547</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5+1G>A</td><td>X</td><td>138630651</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-10.4</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5+1G>T</td><td>X</td><td>138630651</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-5.4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5+2T>A</td><td>X</td><td>138630652</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-5.4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5+2T>C</td><td>X</td><td>138630652</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-5</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5+2T>G</td><td>X</td><td>138630652</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-5.8</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS6+1G>A</td><td>X</td><td>138633424</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>-7.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:c.723G>A</td><td>X</td><td>138633423</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.2</td><td>2.2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor-1G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS6+1G>T</td><td>X</td><td>138633424</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>-2.6</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS6+2T>C</td><td>X</td><td>138633425</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>-2.3</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor1T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:g.138643015G>C</td><td>X</td><td>138643015</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.2</td><td>-0.6</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:g.138643015G>A</td><td>X</td><td>138643015</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.2</td><td>-3.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>von Kodolitsch Y. Haemophilia. 2006;12(3):258-262.</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>TNNT2</td><td>inherited or sporadic</td><td>NM_001276345:IVS16+1G>A</td><td>1</td><td>201328750</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.4</td><td>-5.4</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_001005242:IVS7+1G>A</td><td>12</td><td>32976978</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.4</td><td>-4.4</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS5+1G>A</td><td>12</td><td>33003699</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.8</td><td>-8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS32+2T>A (IVS31)</td><td>11</td><td>47354115</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>2.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS32+1G>A (IVS31)</td><td>11</td><td>47354116</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.8</td><td>-4</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS30+2T>C  (IVS29)</td><td>11</td><td>47354743</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.4</td><td>1</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS30+2T>G  (IVS29)</td><td>11</td><td>47354743</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.4</td><td>0.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor1T>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS30+5G>C  (IVS29)</td><td>11</td><td>47354740</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.4</td><td>4.5</td><td>-3.9</td><td>rs373746463</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor4G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS27+1G>A  (IVS26)</td><td>11</td><td>47356592</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.8</td><td>-8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS21+1G>A (IVS20)</td><td>11</td><td>47361201</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4</td><td>-8.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS15+1G>A (IVS14)</td><td>11</td><td>47364571</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-4.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS17+4A>T (IVS16)</td><td>11</td><td>47364125</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.3</td><td>5.2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor3A>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:g.47367758G>A</td><td>11</td><td>47367758</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.6</td><td>3.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor-1G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS12+1G>A</td><td>11</td><td>47367757</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.6</td><td>-6.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>LMNA</td><td>inherited or sporadic</td><td>NM_170707:IVS6+1G>A (IVS8)</td><td>1</td><td>156106820</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.5</td><td>-2.3</td><td>-12.8</td><td>rs267607640</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DES</td><td>inherited or sporadic</td><td>NM_001927:IVS3+3A>G</td><td>2</td><td>220285071</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>3.3</td><td>2.9</td><td>-0.4</td><td>rs267607483</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor2A>G </td></tr>
<tr><td>Catecholaminergic polymorphic ventricular tachycardia</td><td>1-5 / 10 000</td><td>CASQ2</td><td>autosomal recessive or dominant</td><td>NM_001232:IVS4+1G>A</td><td>1</td><td>116280844</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>-4.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>donor0G>A </td></tr>
<tr><td>Metachromatic Leukodystrophy</td><td>1-9 / 1 000 000</td><td>ARSA</td><td>Autosomal recessive</td><td>NM_001085425:c.1101+1G>T</td><td>22</td><td>51064363</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.6</td><td>0.8</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Kang D. The Korean Journal of Laboratory Medicine. 2010;30(5):516-520.</td><td>donor0G>T </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.453G>A</td><td>X</td><td>103041655</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.8</td><td>3.8</td><td>-3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Cryptic</td><td>"Hobson et al. Human Mutation. 27(1), 69-77."</td><td>donor-1G>A </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.453G>T</td><td>X</td><td>103041655</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.8</td><td>3.5</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Cryptic</td><td>"Hobson et al. Human Mutation. 27(1), 69-77."</td><td>donor-1G>T </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.453G>C</td><td>X</td><td>103041655</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.8</td><td>2.8</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Cryptic</td><td>"Hobson et al. Human Mutation. 27(1), 69-77."</td><td>donor-1G>C </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.453+2T>C</td><td>X</td><td>103041657</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.8</td><td>-0.6</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Cryptic</td><td>"Hobson et al. Human Mutation. 27(1), 69-77."</td><td>donor1T>C </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.453+4A>G</td><td>X</td><td>103041659</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.8</td><td>4.3</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Cryptic</td><td>"Hobson et al. Human Mutation. 27(1), 69-77."</td><td>donor3A>G </td></tr>
<tr><td>Pelizaeus-Merzbacher Disease</td><td>  1-9 / 1 000 000</td><td>PLP1</td><td>X-linked</td><td>NM_000533:c.191+1G>A</td><td>X</td><td>103040698</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.5</td><td>-7.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Laššuthová P. J Child Neurol. 2013</td><td>donor0G>A </td></tr>
<tr><td>Pelizaeus-Merzbacher Disease</td><td>  1-9 / 1 000 000</td><td>PLP1</td><td>X-linked</td><td>NM_000533:c.696+1G>A</td><td>X</td><td>103043440</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.6</td><td>-1.2</td><td>-12.8</td><td>rs113897548</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Laššuthová P. J Child Neurol. 2013</td><td>donor0G>A </td></tr>
<tr><td>Congenital Cataracts</td><td>3/10 000<sup>6</sup></td><td>HSF4</td><td>autosomal recessive</td><td>  NM_001040667:c.1324+4A>G</td><td>16</td><td>67203255</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8</td><td>5.4</td><td>-2.6</td><td>rs371333597</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Skipping</td><td>Smaoui N. Invest Ophthalmol Vis Sci. 2004;45(8):2716-2721.</td><td>donor3A>G </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.5585+1G>A</td><td>1</td><td>94476355</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.2</td><td>-5.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor0G>A </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.4253+5G>T</td><td>1</td><td>94496547</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.2</td><td>4.3</td><td>-3.9</td><td>rs61750138</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor4G>T </td></tr>
<tr><td>Age-related macular degeneration </td><td>>1 / 1000</td><td>ABCA4</td><td>autosomal dominant</td><td>NM_000350:c.5196+1G>A</td><td>1</td><td>94485137</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.8</td><td>-6</td><td>-12.8</td><td>rs61751377</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor0G>A </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.5196+2T>C</td><td>1</td><td>94485136</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.8</td><td>-0.7</td><td>-7.5</td><td>rs61751405</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor1T>C </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.5714+5G>A</td><td>1</td><td>94476351</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.2</td><td>3.7</td><td>-3.5</td><td>rs61751407</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor4G>A </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.5898+1G>T</td><td>1</td><td>94473790</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>0.8</td><td>-7.8</td><td>rs61750638</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor0G>T </td></tr>
<tr><td>Stargardt disease</td><td>1-5 / 10 000</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.6005+1G>T</td><td>1</td><td>94473189</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.2</td><td>3.4</td><td>-7.8</td><td>rs61748517</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>donor0G>T </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1586G>A</td><td>19</td><td>11224438</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>2.3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>donor-1G>A </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.2140+1G>T</td><td>19</td><td>11231199</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.8</td><td>0</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>donor0G>T </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.2389+1G>T</td><td>19</td><td>11238762</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>0.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>donor0G>T </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.2389+1G>A</td><td>19</td><td>11238762</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>-4.7</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>donor0G>A </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.2389+5G>A</td><td>19</td><td>11238766</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.1</td><td>4.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>donor4G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.441+2T>G</td><td>17</td><td>41256137</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>-4.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Cryptic (deletion)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor1T>G </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.547+2T>A</td><td>17</td><td>41251790</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.2</td><td>-7.8</td><td>rs80358047</td><td>0.1</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor1T>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.4986+1G>T</td><td>17</td><td>41222944</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>-2.1</td><td>-7.8</td><td>rs80358162</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor0G>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.5332+1G>A</td><td>17</td><td>41203079</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.5</td><td>-1.3</td><td>-12.8</td><td>rs80358041</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor0G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.475+1G>A</td><td>13</td><td>32900288</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-5.3</td><td>-12.8</td><td>rs81002797</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor0G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.212G>A</td><td>17</td><td>41258473</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>2.9</td><td>-3.1</td><td>rs80356913</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor-1G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.4484G>T</td><td>17</td><td>41228505</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7.7</td><td>-3.3</td><td>rs80357389</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor-1G>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.4986+5G>T</td><td>17</td><td>41222940</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>1.8</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic (retention)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor4G>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.631G>A</td><td>13</td><td>32900750</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.6</td><td>2.6</td><td>-3.1</td><td>rs80358871</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor-1G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.8754+3G>C</td><td>13</td><td>32950931</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>5.6</td><td>-4.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Cryptic (retention)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor2G>C </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.9117G>A</td><td>13</td><td>32954050</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.5</td><td>-0.5</td><td>-3.1</td><td>rs28897756</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>donor-1G>A </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD1</td><td>autosomal dominant</td><td>NM_001009944:IVS4+1G>A</td><td>16</td><td>2168676</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>-3.4</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>donor0G>A </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD1</td><td>autosomal dominant</td><td>NM_001009944:IVS19+1G>T</td><td>16</td><td>2156091</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.7</td><td>2.9</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>donor0G>T </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD1</td><td>autosomal dominant</td><td>NM_001009944:IVS24+5G>C</td><td>16</td><td>2152810</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.9</td><td>3</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>donor4G>C </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD2</td><td>autosomal dominant</td><td>NM_000297:IVS8+5G>A</td><td>4</td><td>88977424</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.8</td><td>4.3</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>donor4G>A </td></tr>
<tr><td>Gitelman Syndrome</td><td>1/50 000</td><td>SLC12A3</td><td>autosomal recessive</td><td>  NM_000339:c.2633+1G>C </td><td>16</td><td>56928555</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-4.3</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Godefroid N. Am J Kidney Dis. 2006;48(5):e73-9.</td><td>donor0G>C </td></tr>
<tr><td>Hailey-Hailey Disease</td><td>unknown - rare</td><td>ATP2C1</td><td>autosomal dominant</td><td>NM_014382:c.1570+2T>C</td><td>3</td><td>130694334</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.1</td><td>2.7</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Hamada T. J Dermatol Sci. 2008;51(1):31-36.</td><td>donor1T>C </td></tr>
<tr><td>Hailey-Hailey Disease</td><td>unknown - rare</td><td>ATP2C1</td><td>autosomal dominant</td><td>NM_014382:c.899+1G>T</td><td>3</td><td>130678186</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.4</td><td>4.6</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Hamada T. J Dermatol Sci. 2008;51(1):31-36.</td><td>donor0G>T </td></tr>
<tr><td>Hailey-Hailey Disease</td><td>unknown - rare</td><td>ATP2C1</td><td>autosomal dominant</td><td>NM_014382:c.899+1G>T</td><td>3</td><td>130678186</td><td>Cryptic</td><td>DONOR</td><td>Strengthened</td><td>5.2</td><td>6.4</td><td>1.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-5</td><td>N</td><td>-</td><td>Hamada T. J Dermatol Sci. 2008;51(1):31-36.</td><td>donor-5G>T </td></tr>
<tr><td>Hailey-Hailey Disease</td><td>unknown - rare</td><td>ATP2C1</td><td>autosomal dominant</td><td>NM_014382:c.360+1G>C</td><td>3</td><td>130656308</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.7</td><td>2.9</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Hamada T. J Dermatol Sci. 2008;51(1):31-36.</td><td>donor0G>C </td></tr>
<tr><td>Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)</td><td>  <1 / 1 000 000</td><td>CLDN16</td><td>autosomal recessive</td><td>NM_006580:c.784+1G>T</td><td>3</td><td>190126295</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>3.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Hampson G. BMC Nephrol. 2008;9:12</td><td>donor0G>T </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:IVS9+3C>A</td><td>7</td><td>117182165</td><td>Natural</td><td>DONOR</td><td>strengthen</td><td>5.2</td><td>10</td><td>4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Increased Skipping</td><td>Hefferon TW. The American Journal of Human Genetics. 2002;71(2):294-303.</td><td>donor2C>A </td></tr>
<tr><td>Glycerol Kinase Deficiency</td><td>unknown - rare</td><td>GK</td><td>X-linked recessive</td><td>NM_203391:IVS1+4A>G</td><td>X</td><td>30671736</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7</td><td>4.4</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Skipping</td><td>Hellerud C. Mol Genet Metab. 2003;79(3):149-159.</td><td>donor3A>G </td></tr>
<tr><td>Severe Hypertriglyceridemia</td><td>1.1% of adults<sup>3</sup></td><td>APOA5</td><td>autosomal recessive</td><td>NM_052968:c.161+5G>C</td><td>11</td><td>116662297</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.4</td><td>2.4</td><td>-3.9</td><td>rs200831171</td><td>0.05</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Henneman P. J Intern Med. 2008;263(1):107-108.</td><td>donor4G>C </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.914+5G>C</td><td>7</td><td>286478</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.7</td><td>6.8</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>donor4G>C </td></tr>
<tr><td>Parkinson's Disease</td><td>1% of population >502</td><td>LRRK2</td><td>autosomal dominant</td><td>NM_198578:IVS33+6T>A</td><td>12</td><td>40709108</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.1</td><td>4.5</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Skipper L. Neurology. 2005;65(8):1319-1321</td><td>donor5T>A </td></tr>
<tr><td>Batten disease</td><td>1-9 / 1 000 000</td><td>CLN3</td><td>autosomal recessive</td><td>NM_001042432:c.1056G>C</td><td>16</td><td>28493426</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.1</td><td>0.1</td><td>-4</td><td>rs386833699</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Leman AR. Hum Genet. 2005;116(3):236</td><td>donor-1G>C </td></tr>
<tr><td>Congenital Cataracts</td><td>3/10 000<sup>6</sup></td><td>CRYBA1</td><td>autosomal dominant</td><td>NM_005208:c.215+1G>A</td><td>17</td><td>27577319</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-6.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Kannabiran C.Mol Vis. 1998;4:21.</td><td>donor0G>A </td></tr>
<tr><td>Dystrophic epidermolysis bullosa</td><td>1-9 / 100 000</td><td>COL7A1</td><td>autosomal recessive or dominant</td><td>NM_000094:c.5771A>C</td><td>3</td><td>48613834</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.9</td><td>8.9</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Wessagowit V. J Invest Dermatol. 2005;124(4):863-866.</td><td>donor-2A>C </td></tr>
<tr><td>Isovaleric acidemia</td><td>1-9 / 100 000</td><td>IVD</td><td>Autosomal recessive</td><td>NM_002225:c.465+2T>C</td><td>15</td><td>40702998</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>3.5</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No detectable transcript</td><td>Vockley J. Am J Hum Genet. 2000;66(2):356-367.</td><td>donor1T>C </td></tr>
<tr><td>Isovaleric acidemia</td><td>1-9 / 100 000</td><td>IVD</td><td>Autosomal recessive</td><td>NM_002225:c.465+1G>A</td><td>15</td><td>40702997</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11</td><td>-1.9</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Vockley J. Am J Hum Genet. 2000;66(2):356-367.</td><td>donor0G>A </td></tr>
<tr><td>Knobloch syndrome</td><td>  <1 / 1 000 000</td><td>COL18A1</td><td>autosomal recessive</td><td> NM_030582:c.3544+3A>C</td><td>21</td><td>46925195</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7</td><td>2.2</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Keren B. Am J Med Genet A. 2007;143A(13):1514-1518.</td><td>donor2A>C </td></tr>
<tr><td>Xeroderma pigmentosum</td><td>  <1 / 1 000 000</td><td>XPC</td><td>autosomal recessive</td><td>NM_004628:c.2033+2T>G</td><td>3</td><td>14197833</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.7</td><td>1.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>Khan SG. J Invest Dermatol. 1998;111(5):791-796</td><td>donor1T>G </td></tr>
<tr><td>X-Linked hypophosphatemic rickets </td><td><1 / 1 000 000</td><td>PHEX</td><td>X-linked dominant</td><td>  NM_000444:c.1768+5G>A </td><td>X</td><td>22237225</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.5</td><td>6.9</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Song HR. J Korean Med Sci. 2007;22(6):981-986</td><td>donor4G>A </td></tr>
<tr><td>Manitoba-oculo-tricho-anal Syndrome</td><td>unknown - rare</td><td>FREM1</td><td>autosomal recessive</td><td>NM_144966:c.5556A>G</td><td>9</td><td>14750126</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.6</td><td>0.3</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-2</td><td>Y</td><td>Skipping</td><td>Slavotinek AM. J Med Genet. 2011;48(6):375-382.</td><td>donor-2A>G </td></tr>
<tr><td>Dravet Syndrome</td><td>unknown</td><td>SCN1A</td><td>autosomal dominant</td><td>NM_006920:c.4284+4A>T</td><td>2</td><td>166856229</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>6.2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Lim BC. Seizure. 2011;20(10):789-794.</td><td>donor3A>T </td></tr>
<tr><td>Isovaleric acidemia</td><td>"1:250 000 USA, 1:62 500 Germany"</td><td>IVD</td><td>autosomal recessive</td><td>NM_002225:c.153+1G>T</td><td>15</td><td>40698173</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>3.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention)</td><td>Lee Y. Mol Genet Metab. 2007;92(1):71-77.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>ADA</td><td>-</td><td>NM_000022:IVS5+6T>C</td><td>20</td><td>43254204</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>5.8</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>ADA</td><td>-</td><td>NM_000022:IVS2+1G>A</td><td>20</td><td>43264867</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.5</td><td>-0.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>CAT</td><td>-</td><td>NM_001752:IVS4+5G>A</td><td>11</td><td>34473759</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.4</td><td>2.9</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS23+1G>C</td><td>7</td><td>117282648</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.9</td><td>1.1</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:g.117282647G>C</td><td>7</td><td>117282647</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.9</td><td>6.9</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1G>C </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS14+1G>A</td><td>7</td><td>117232712</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>-2.8</td><td>-12.8</td><td>rs141158996</td><td>0.03</td><td>0.001</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL1A1</td><td>-</td><td>NM_000088:IVS14+5G>A</td><td>17</td><td>48273670</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.2</td><td>2.7</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL1A1</td><td>-</td><td>NM_000088:g.48275794G>A</td><td>17</td><td>48275794</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.4</td><td>5.4</td><td>-3.1</td><td>rs72667022</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL1A2</td><td>-</td><td>NM_000089:IVS6+1G>T</td><td>7</td><td>94030933</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>-2.4</td><td>-7.8</td><td>rs67398234</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>COL1A2</td><td>-</td><td>NM_000089:IVS6+2T>C</td><td>7</td><td>94030934</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>-2.1</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>COL1A2</td><td>-</td><td>NM_000089:g.94030932G>A</td><td>7</td><td>94030932</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.4</td><td>2.4</td><td>-3.1</td><td>rs72656356</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL1A2</td><td>-</td><td>NM_000089:IVS33+5G>A</td><td>7</td><td>94047869</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.7</td><td>3.2</td><td>-3.5</td><td>rs72658157</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL3A1</td><td>-</td><td>NM_000090:IVS40+1G>A</td><td>2</td><td>189869091</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.2</td><td>-0.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>DMD</td><td>-</td><td>NM_000109:IVS26+2T>G</td><td>X</td><td>32472777</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-0.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>DMD</td><td>-</td><td>NM_000109:IVS68+2T>A</td><td>X</td><td>31200853</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>A </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:g.138619545G>A</td><td>X</td><td>138619545</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS1+5G>A</td><td>X</td><td>138613016</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>1.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS2+6T>C</td><td>X</td><td>138619338</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.1</td><td>5.7</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS3+2T>C</td><td>X</td><td>138619547</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>0.1</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS3+2T>G</td><td>X</td><td>138619547</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS5+1G>T</td><td>X</td><td>138630651</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.4</td><td>-5.4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS6+1G>A</td><td>X</td><td>138633424</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>-7.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS6+1G>T</td><td>X</td><td>138633424</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>-2.6</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>GBA</td><td>-</td><td>NM_000157:IVS2+1G>A</td><td>1</td><td>155210420</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.7</td><td>-0.1</td><td>-12.8</td><td>rs104886460</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>GH (GH1)</td><td>-</td><td>NM_000515:IVS3+6T>C</td><td>17</td><td>61995371</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.1</td><td>3.6</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>GH (GH1)</td><td>-</td><td>NM_000515:IVS4+1G>C</td><td>17</td><td>61995119</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>-1.7</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>GH (GH1)</td><td>-</td><td>NM_000515:IVS4+1G>T</td><td>17</td><td>61995119</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>0.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>GLA</td><td>-</td><td>NM_000169:IVS2+2T>G</td><td>X</td><td>100658797</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.9</td><td>-1.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>GLA</td><td>-</td><td>NM_000169:IVS6+1G>T</td><td>X</td><td>100653357</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.2</td><td>1.4</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>GYPB</td><td>-</td><td>NM_002100:c.173C>A</td><td>4</td><td>144920566</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>8.9</td><td>-0.2</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-3C>A </td></tr>
<tr><td>-</td><td>-</td><td>GYPB</td><td>-</td><td>NM_002100:IVS3+1G>T</td><td>4</td><td>144920563</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>1.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>HEXA</td><td>-</td><td>NM_000520: g.72645409G>A</td><td>15</td><td>72645409</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.2</td><td>2.2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>HEXA</td><td>-</td><td>NM_000520:IVS12+1G>C</td><td>15</td><td>72638575</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.8</td><td>0</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>HPRT (HPRT1)</td><td>-</td><td>NM_000194:IVS8+5G>A</td><td>X</td><td>133632719</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>5.7</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>LFA1 (ITGB2)</td><td>-</td><td>NM_000211:g.46330640G>C</td><td>21</td><td>46330640</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>4.6</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1G>C </td></tr>
<tr><td>-</td><td>-</td><td>LIPA</td><td>-</td><td>NM_000235:g.90982268G>A</td><td>10</td><td>90982268</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.8</td><td>5.7</td><td>-3.1</td><td>rs116928232</td><td>0.07</td><td>0.001</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>LPL</td><td>-</td><td>NM_000237:IVS1+5G>C</td><td>8</td><td>19797044</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.7</td><td>5.8</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>C </td></tr>
<tr><td>-</td><td>-</td><td>NF1</td><td>-</td><td>NM_000267:IVS18+1G>A (IVS23)</td><td>17</td><td>29557401</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.2</td><td>-2.6</td><td>-12.8</td><td>rs267606599</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>OTC</td><td>-</td><td>NM_000531:IVS7+2T>C</td><td>X</td><td>38268050</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.5</td><td>-0.9</td><td>-7.5</td><td>rs72558431</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>PBGD (HMBS)</td><td>-</td><td>NM_000190:g.118955776G>T</td><td>11</td><td>118955776</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.2</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>T </td></tr>
<tr><td>-</td><td>-</td><td>PBGD (HMBS)</td><td>-</td><td>NM_000190:IVS1+1G>A</td><td>11</td><td>118955777</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>-3.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>RB (RB1)</td><td>-</td><td>NM_000321:IVS10+1G>T</td><td>13</td><td>48941740</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.3</td><td>-3.5</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>RB (RB1)</td><td>-</td><td>NM_000321:IVS19+2T>C</td><td>13</td><td>49030487</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>0.6</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>VWF</td><td>-</td><td>NM_000552:IVS50+3G>T</td><td>12</td><td>6061007</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.4</td><td>5.3</td><td>-4.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor2G>T </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492.3:c.3873G>C</td><td>7</td><td>117282647</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.9</td><td>6.9</td><td>-4</td><td>rs121909015</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>C </td></tr>
<tr><td>-</td><td>-</td><td>GH (GH1)</td><td>-</td><td>NM_000515:IVS2+1G>A</td><td>17</td><td>61995705</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>-9.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:g.5248160G>C</td><td>11</td><td>5248160</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>1.6</td><td>-4</td><td>rs33960103</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor-1G>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+5G>A</td><td>11</td><td>5248155</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>2.1</td><td>-3.5</td><td>rs33915217</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+1G>C</td><td>11</td><td>5248159</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>-4.1</td><td>-9.8</td><td>rs33971440</td><td>0.04</td><td>0.001</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+5G>C</td><td>11</td><td>5248155</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>1.7</td><td>-3.9</td><td>rs33915217</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+5G>T</td><td>11</td><td>5248155</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>1.8</td><td>-3.9</td><td>rs33915217</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor4G>T </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+6T>C</td><td>11</td><td>5248154</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>4.2</td><td>-1.4</td><td>rs35724775</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>5</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1+2T>G</td><td>11</td><td>5248158</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>-2.5</td><td>-8.2</td><td>rs33956879</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>ADA</td><td>-</td><td>NM_000022:IVS10+1G>A</td><td>20</td><td>43249658</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.6</td><td>-2.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS14+1G>A</td><td>7</td><td>117232712</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>-2.8</td><td>-12.8</td><td>rs141158996</td><td>0.03</td><td>0.001</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>CETP</td><td>Autosomal Recessive</td><td>NM_000078:IVS10+2T>G</td><td>16</td><td>57009065</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-0.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor1T>G </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:IVS2+5G>C</td><td>8</td><td>19805856</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.7</td><td>5.8</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor4G>C </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS3+1G>A</td><td>19</td><td>11213463</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>-7</td><td>-12.8</td><td>rs112029328</td><td>0.1</td><td>0.004</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS3+1G>T</td><td>19</td><td>11213463</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>-2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>T </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS4+2T>C</td><td>19</td><td>11216278</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-1.8</td><td>-7.5</td><td>rs200238879</td><td>0.15</td><td>0.003</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor1T>C </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LIPA</td><td>Autosomal Recessive</td><td>NM_000235:g.90982268G>A</td><td>10</td><td>90982268</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.8</td><td>5.7</td><td>-3.1</td><td>rs116928232</td><td>0.07</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor-1G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>APOA-II</td><td>Autosomal Recessive</td><td>NM_001643:IVS3+1G>A</td><td>1</td><td>161192707</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>-3.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>APOB</td><td>Autosomal Recessive</td><td>NM_000384:IVS5+1G>T</td><td>2</td><td>21260829</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9</td><td>1.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>T </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>APOC-II</td><td>Autosomal Recessive</td><td>NM_000483:IVS2+1G>C</td><td>19</td><td>45451791</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9</td><td>-0.8</td><td>-9.8</td><td>rs111628497</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>C </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS9+1G>A</td><td>19</td><td>11224126</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.3</td><td>-1.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS10+5G>A</td><td>19</td><td>11224443</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.4</td><td>1.9</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor4G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS11+1G>T</td><td>19</td><td>11226889</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-0.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>T </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS12+2T>C</td><td>19</td><td>11227676</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.6</td><td>-0.8</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor1T>C </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:g.19805851G>A</td><td>8</td><td>19805851</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.7</td><td>6.7</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor-1G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:IVS15+1G>A</td><td>19</td><td>11234021</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.8</td><td>-5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>APOB</td><td>Autosomal Recessive</td><td>NM_000384:IVS24+2T>C</td><td>2</td><td>21237318</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.9</td><td>0.4</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor1T>C </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>CETP</td><td>Autosomal Recessive</td><td>NM_000078:IVS14+1G>A</td><td>16</td><td>57016150</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7</td><td>-5.8</td><td>-12.8</td><td>rs5742907</td><td>0.13</td><td>0.002</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:g.11222315G>A</td><td>19</td><td>11222315</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7</td><td>4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor-1G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:g.11238761G>A</td><td>19</td><td>11238761</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.1</td><td>5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5 / 10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+1G>A (IVS2)</td><td>17</td><td>41276033</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.4</td><td>-2.4</td><td>-12.8</td><td>rs80358010</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+1G>C (IVS2)</td><td>17</td><td>41276033</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.4</td><td>0.6</td><td>-9.8</td><td>rs80358010</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+1G>T (IVS2)</td><td>17</td><td>41276033</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.4</td><td>2.6</td><td>-7.8</td><td>rs80358010</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+2T>G (IVS2)</td><td>17</td><td>41276032</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.4</td><td>2.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+4A>T (IVS2)</td><td>17</td><td>41276030</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.4</td><td>7.3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.80+5G>A (IVS2)</td><td>17</td><td>41276029</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.4</td><td>6.9</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+1G>C (IVS3)</td><td>17</td><td>41267742</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>-0.7</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+2T>C (IVS3)</td><td>17</td><td>41267741</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>1.7</td><td>-7.5</td><td>rs80358131</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+2T>G (IVS3)</td><td>17</td><td>41267741</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>0.9</td><td>-8.2</td><td>rs80358131</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+3A>C (IVS3)</td><td>17</td><td>41267740</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>4.4</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+5G>A (IVS3)</td><td>17</td><td>41267738</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>5.6</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134A>C</td><td>17</td><td>41267743</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>8.2</td><td>-1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.189A>T</td><td>17</td><td>41258496</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.2</td><td>4.1</td><td>-2.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.191G>A</td><td>17</td><td>41258494</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.2</td><td>-6.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.211A>G</td><td>17</td><td>41258474</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>3.7</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+1G>A (IVS5)</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-6.8</td><td>-12.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+1G>C (IVS5)</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-3.8</td><td>-9.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+1G>T (IVS5)</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-1.8</td><td>-7.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+2T>C (IVS5)</td><td>17</td><td>41258471</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-1.5</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212G>A</td><td>17</td><td>41258473</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>2.9</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.301+5G>A (IVS6)</td><td>17</td><td>41256880</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.4</td><td>3.8</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.547+1G>A (IVS8)</td><td>17</td><td>41251791</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-4.8</td><td>-12.8</td><td>rs80358030</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.547+1G>T (IVS8)</td><td>17</td><td>41251791</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.2</td><td>-7.8</td><td>rs80358030</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.547+2T>A (IVS8)</td><td>17</td><td>41251790</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.593+4A>G (IVS9)</td><td>17</td><td>41249257</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.1</td><td>9.6</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4096+1G>A (IVS11)</td><td>17</td><td>41243451</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.3</td><td>-9.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4184A>G</td><td>17</td><td>41242962</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>5.3</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4185+1G>T (IVS12)</td><td>17</td><td>41242960</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4185G>A</td><td>17</td><td>41242961</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4183C>T</td><td>17</td><td>41242963</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>6</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+1G>A (IVS13)</td><td>17</td><td>41234420</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>-3.7</td><td>-12.8</td><td>rs80358027</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+1G>A (IVS13)</td><td>17</td><td>41234420</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>-3.7</td><td>-12.8</td><td>rs80358027</td><td>0</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+1G>T (IVS13)</td><td>17</td><td>41234420</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>1.3</td><td>-7.8</td><td>rs80358027</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+2T>G (IVS13)</td><td>17</td><td>41234419</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>0.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+2T>G (IVS13)</td><td>17</td><td>41234419</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.1</td><td>0.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4357+6T>C (IVS13)</td><td>17</td><td>41234415</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>7.7</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4484+1G>A (IVS14)</td><td>17</td><td>41228504</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11</td><td>-1.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4484G>A</td><td>17</td><td>41228505</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7.9</td><td>-3.1</td><td>rs80357389</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4484G>T </td><td>17</td><td>41228505</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7.7</td><td>-3.3</td><td>rs80357389</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4675+1G>A (IVS15)</td><td>17</td><td>41226347</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.1</td><td>-7.7</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4675+3A>T (IVS15)</td><td>17</td><td>41226345</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.1</td><td>0.6</td><td>-4.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4675G>A</td><td>17</td><td>41226348</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.1</td><td>2</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4675G>C</td><td>17</td><td>41226348</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.1</td><td>1</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+1G>A (IVS16)</td><td>17</td><td>41222944</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>-7.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+3G>C (IVS16)</td><td>17</td><td>41222942</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>1.3</td><td>-4.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+4A>C (IVS16)</td><td>17</td><td>41222941</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>2.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+4A>T (IVS16)</td><td>17</td><td>41222941</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>2.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+6T>C (IVS16)</td><td>17</td><td>41222939</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>4.3</td><td>-1.4</td><td>rs80358086</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+6T>G (IVS16)</td><td>17</td><td>41222939</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>4.5</td><td>-1.2</td><td>rs80358086</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5072C>T</td><td>17</td><td>41219627</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>4.5</td><td>2.9</td><td>-1.6</td><td>rs80357034</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5073A>G</td><td>17</td><td>41219626</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>2.2</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074+1G>A (IVS17)</td><td>17</td><td>41219624</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-8.3</td><td>-12.8</td><td>rs80358053</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074+1G>T (IVS17)</td><td>17</td><td>41219624</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3.3</td><td>-7.8</td><td>rs80358053</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074+2T>C (IVS17)</td><td>17</td><td>41219623</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074G>A</td><td>17</td><td>41219625</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>1.4</td><td>-3.1</td><td>rs80187739</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074G>C</td><td>17</td><td>41219625</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>0.4</td><td>-4</td><td>rs80187739</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5074G>T</td><td>17</td><td>41219625</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>1.2</td><td>-3.3</td><td>rs80187739</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+1G>C (IVS18)</td><td>17</td><td>41215890</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>-4</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+1G>T (IVS18)</td><td>17</td><td>41215890</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>-2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+3A>C (IVS18)</td><td>17</td><td>41215888</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>1</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+5G>A (IVS18)</td><td>17</td><td>41215886</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>2.3</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+6T>A (IVS18)</td><td>17</td><td>41215885</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.8</td><td>4.2</td><td>-1.6</td><td>rs80358074</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+6T>C (IVS18)</td><td>17</td><td>41215885</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.8</td><td>4.4</td><td>-1.4</td><td>rs80358074</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+6T>G (IVS18)</td><td>17</td><td>41215885</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.8</td><td>4.6</td><td>-1.2</td><td>rs80358074</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5193+1G>A (IVS19)</td><td>17</td><td>41215349</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.6</td><td>-1.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5277+1G>A (IVS20)</td><td>17</td><td>41209068</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-5.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5277G>A</td><td>17</td><td>41209069</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5332+1G>A (IVS21)</td><td>17</td><td>41203079</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.5</td><td>-1.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5332+2T>A (IVS21)</td><td>17</td><td>41203078</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.5</td><td>3.8</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5332+4A>G (IVS21)</td><td>17</td><td>41203076</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.5</td><td>9</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5332G>A (p.D1778N)</td><td>17</td><td>41203080</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.5</td><td>8.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5406+1G>A (IVS22)</td><td>17</td><td>41201137</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-5.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5406+5G>A (IVS22)</td><td>17</td><td>41201133</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>4</td><td>-3.5</td><td>rs80358073</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5406+5G>T (IVS22)</td><td>17</td><td>41201133</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>3.6</td><td>-3.9</td><td>rs80358073</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5467+1G>A (IVS23)</td><td>17</td><td>41199659</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>-4.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5467+2T>C (IVS23)</td><td>17</td><td>41199658</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>1.2</td><td>-7.5</td><td>rs80358009</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5467+2T>G (IVS23)</td><td>17</td><td>41199658</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>0.5</td><td>-8.2</td><td>rs80358009</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5467G>A (p.A1823T)</td><td>17</td><td>41199660</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.7</td><td>5.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.67+1G>T (IVS2)</td><td>13</td><td>32890665</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3.3</td><td>-7.8</td><td>rs81002796</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.67+1G>A (IVS2)</td><td>13</td><td>32890665</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-8.3</td><td>-12.8</td><td>rs81002796</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.67+2T>A (IVS2)</td><td>13</td><td>32890666</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3.3</td><td>-7.8</td><td>rs81002885</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.67+2T>C (IVS2)</td><td>13</td><td>32890666</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.5</td><td>-3</td><td>-7.5</td><td>rs81002885</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.316+5G>A (IVS3)</td><td>13</td><td>32893467</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>7.6</td><td>-3.5</td><td>rs81002840</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.316+6T>C (IVS3)</td><td>13</td><td>32893468</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>9.7</td><td>-1.4</td><td>rs81002900</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.316+2T>C (IVS3)</td><td>13</td><td>32893464</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.1</td><td>3.7</td><td>-7.5</td><td>rs81002805</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.475+3A>T (IVS5)</td><td>13</td><td>32900290</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>3</td><td>-4.5</td><td>rs81002795</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.473C>T (p.S158L)</td><td>13</td><td>32900285</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>5.9</td><td>-1.6</td><td>rs80358701</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.475G>A (p.V159M)</td><td>13</td><td>32900287</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>4.5</td><td>-3.1</td><td>rs80358702</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.475+1G>T (IVS5)</td><td>13</td><td>32900288</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-0.3</td><td>-7.8</td><td>rs81002797</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.475+1G>A (IVS5)</td><td>13</td><td>32900288</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-5.3</td><td>-12.8</td><td>rs81002797</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.516G>A (p.K172K)</td><td>13</td><td>32900419</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>6</td><td>-3.1</td><td>rs80359790</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631G>C (p.V211L)</td><td>13</td><td>32900750</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>1.6</td><td>-4</td><td>rs80358871</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631G>A (p.V211I)</td><td>13</td><td>32900750</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.6</td><td>2.6</td><td>-3.1</td><td>rs80358871</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631+1G>A (IVS7)</td><td>13</td><td>32900751</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-7.2</td><td>-12.8</td><td>rs81002897</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631+2T>G (IVS7)</td><td>13</td><td>32900752</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-2.6</td><td>-8.2</td><td>rs81002899</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.793+1G>T (IVS9)</td><td>13</td><td>32905168</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.2</td><td>2.4</td><td>-7.8</td><td>rs81002846</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.793+1G>A (IVS9)</td><td>13</td><td>32905168</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.2</td><td>-2.6</td><td>-12.8</td><td>rs81002846</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6841+3A>T (IVS11)</td><td>13</td><td>32915336</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.2</td><td>4.7</td><td>-4.5</td><td>rs81002825</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6935A>T (p.D2312V)</td><td>13</td><td>32918788</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>4.8</td><td>3.4</td><td>-1.4</td><td>rs80358916</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007+5G>C (IVS13)</td><td>13</td><td>32921038</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>3.4</td><td>-3.9</td><td>rs81002816</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007+5G>A (IVS13)</td><td>13</td><td>32921038</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>3.8</td><td>-3.5</td><td>rs81002816</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007G>C (p.R2336P)</td><td>13</td><td>32921033</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.3</td><td>3.3</td><td>-4</td><td>rs28897743</td><td>1.09</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007G>T (p.R2336L)</td><td>13</td><td>32921033</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>4</td><td>-3.3</td><td>rs28897743</td><td>1.09</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007G>A (p.R2336H)</td><td>13</td><td>32921033</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>4.3</td><td>-3.1</td><td>rs28897743</td><td>1.09</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7617+1G>A (IVS15)</td><td>13</td><td>32930747</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>-2.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7617+1G>T (IVS15)</td><td>13</td><td>32930747</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>2.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7617+2T>G (IVS15)</td><td>13</td><td>32930748</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10</td><td>1.8</td><td>-8.2</td><td>rs81002843</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor1T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7805+3A>C (IVS16)</td><td>13</td><td>32932069</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.2</td><td>-2.6</td><td>-4.8</td><td>rs81002810</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7805+1G>A (IVS16)</td><td>13</td><td>32932067</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.2</td><td>-10.6</td><td>-12.8</td><td>rs81002809</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7976G>C (p.R2659T)</td><td>13</td><td>32936830</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.7</td><td>0.7</td><td>-4</td><td>rs80359027</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7976G>A (p.R2659K)</td><td>13</td><td>32936830</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.7</td><td>1.7</td><td>-3.1</td><td>rs80359027</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7975A>G (p.R2659G)</td><td>13</td><td>32936829</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>4.7</td><td>2.4</td><td>-2.3</td><td>rs80359026</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7976+1G>A (IVS17)</td><td>13</td><td>32936831</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.7</td><td>-8.1</td><td>-12.8</td><td>rs81002873</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7974C>G (p.Y2658X)</td><td>13</td><td>32936828</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>4.7</td><td>3.6</td><td>-1.2</td><td>rs80359025</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8331+1G>T (IVS18)</td><td>13</td><td>32937671</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.5</td><td>0.7</td><td>-7.8</td><td>rs81002837</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8486A>T (p.Q2829L)</td><td>13</td><td>32944693</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>5.4</td><td>-2.1</td><td>rs80359100</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8487+1G>A (IVS19)</td><td>13</td><td>32944695</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-5.3</td><td>-12.8</td><td>rs81002798</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8487G>A (p.Q2829Q)</td><td>13</td><td>32944694</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>4.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8485C>T (p.Q2829X)</td><td>13</td><td>32944692</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.5</td><td>5.9</td><td>-1.6</td><td>rs80359099</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8754+5G>T (IVS21)</td><td>13</td><td>32950933</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>6.1</td><td>-3.9</td><td>rs81002813</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8754+5G>A (IVS21)</td><td>13</td><td>32950933</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>6.5</td><td>-3.5</td><td>rs81002813</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8754+4A>G (IVS21)</td><td>13</td><td>32950932</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>7.4</td><td>-2.6</td><td>rs81002893</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8754G>A (p.E2918E)</td><td>13</td><td>32950928</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>6.9</td><td>-3.1</td><td>rs80359803</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8953+1G>T (IVS22)</td><td>13</td><td>32953653</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.7</td><td>4.9</td><td>-7.8</td><td>rs81002882</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8951C>G (p.S2984X)</td><td>13</td><td>32953650</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.7</td><td>11.6</td><td>-1.2</td><td>rs80359146</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9117+1G>T (IVS23)</td><td>13</td><td>32954051</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.5</td><td>-5.3</td><td>-7.8</td><td>rs81002802</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9117+1G>A (IVS23)</td><td>13</td><td>32954051</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.5</td><td>-10.3</td><td>-12.8</td><td>rs81002802</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9117G>A (p.P3039P)</td><td>13</td><td>32954050</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.5</td><td>-0.5</td><td>-3.1</td><td>rs28897756</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9256+1G>A (IVS24)</td><td>13</td><td>32954283</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.4</td><td>-5.4</td><td>-12.8</td><td>rs81002883</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9256G>T (p.G3086X)</td><td>13</td><td>32954282</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.4</td><td>4.1</td><td>-3.3</td><td>rs80359192</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9501+3A>T (IVS25)</td><td>13</td><td>32969073</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>5.3</td><td>-4.5</td><td>rs61757642</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9501+4A>G (IVS25)</td><td>13</td><td>32969074</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>7.3</td><td>-2.6</td><td>rs81002848</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9500A>C (p.E3167A)</td><td>13</td><td>32969069</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>7.8</td><td>-2</td><td>rs80359223</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9501G>A (p.E3167E)</td><td>13</td><td>32969070</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>6.8</td><td>-3.1</td><td>rs80359808</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9646C>T (p.L3216L)</td><td>13</td><td>32971179</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10.1</td><td>8.5</td><td>-1.6</td><td>rs80359809</td><td>-</td><td>-</td><td>Synonymous</td><td>-3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-3C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+3A>G (IVS5)</td><td>17</td><td>41258470</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>5.6</td><td>-0.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.212+1G>A (IVS5)</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-6.8</td><td>-12.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5277+1G>A (IVS20)</td><td>17</td><td>41209068</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-5.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5152+5G>A (IVS18)</td><td>17</td><td>41215886</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.8</td><td>2.3</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor4G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4484G>A (p.R1495K)</td><td>17</td><td>41228505</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7.9</td><td>-3.1</td><td>rs80357389</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4185G>A (p.Q1395Q)</td><td>17</td><td>41242961</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.134+3A>C (IVS3)</td><td>17</td><td>41267740</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>4.4</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9117G>A (p.P3039P)</td><td>13</td><td>32954050</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.5</td><td>-0.5</td><td>-3.1</td><td>rs28897756</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631+3A>G (IVS7)</td><td>13</td><td>32900753</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.6</td><td>5.2</td><td>-0.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7976G>A (p.R2659K)</td><td>13</td><td>32936830</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.7</td><td>1.7</td><td>-3.1</td><td>rs80359027</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7976G>C (p.R2659T)</td><td>13</td><td>32936830</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.7</td><td>0.7</td><td>-4</td><td>rs80359027</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7007G>A (p.R2336H)</td><td>13</td><td>32921033</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>4.3</td><td>-3.1</td><td>rs28897743</td><td>1.09</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.631G>A (p.V211I)</td><td>13</td><td>32900750</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.6</td><td>2.6</td><td>-3.1</td><td>rs80358871</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8331G>A (p.K2776K)</td><td>13</td><td>32937670</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.5</td><td>5.5</td><td>-3.1</td><td>rs80359802</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>N</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.441+1G>A (IVS7)</td><td>17</td><td>41256138</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>-9.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+6T>G (IVS16)</td><td>17</td><td>41222939</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>4.5</td><td>-1.2</td><td>rs80358086</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>N</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor5T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.211A>G (p.R71G)</td><td>17</td><td>41258474</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>3.7</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>N</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor-2A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8754+4A>G (IVS21)</td><td>13</td><td>32950932</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>10</td><td>7.4</td><td>-2.6</td><td>rs81002893</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>G </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2C19</td><td>-</td><td>NM_000769:IVS5+2T>A</td><td>10</td><td>96541756</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.9</td><td>-0.9</td><td>-7.8</td><td>rs72558186</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>Rogan PK. Pharmacogenetics. 2003;13(4):207-218.</td><td>donor1T>A </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2D6</td><td>-</td><td>NM_000106:g.42525035G>T</td><td>22</td><td>42525035</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.1</td><td>4.8</td><td>-3.3</td><td>rs5030865</td><td>0.09</td><td>0.002</td><td>Nonsense</td><td>-1</td><td>N</td><td>-</td><td>Rogan PK. Pharmacogenetics. 2003;13(4):207-218.</td><td>donor-1G>T </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2D6</td><td>-</td><td>NM_000106:g.42525035G>A</td><td>22</td><td>42525035</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.1</td><td>5.1</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>Rogan PK. Pharmacogenetics. 2003;13(4):207-218.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>MFN2</td><td>-</td><td>NM_014874:g.12064177T>G</td><td>1</td><td>12064177</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.7</td><td>2.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>VPS13D</td><td>-</td><td>NM_018156:g.12318166T>C</td><td>1</td><td>12318166</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>13</td><td>11.6</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>SOAT1</td><td>-</td><td>NM_003101:g.179310449A>G</td><td>1</td><td>179310449</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>8.4</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor3A>G </td></tr>
<tr><td>-</td><td>-</td><td>RP11-342M1.4.1 (NOT ERMAP)</td><td>-</td><td>NM_018538:g.43308444T>G</td><td>1</td><td>43308444</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.9</td><td>2.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>PRMT3</td><td>-</td><td>AK301449:g.20529886G>A</td><td>11</td><td>20529886</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.6</td><td>-7.2</td><td>-12.8</td><td>rs6483700</td><td>0.48</td><td>0.007</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>EEF1G</td><td>-</td><td>NM_001404:g.62341301T>G</td><td>11</td><td>62341301</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.8</td><td>0.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>GCN1L1</td><td>-</td><td>NM_006836:g.120613944T>G</td><td>12</td><td>120613944</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.2</td><td>2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>GPR133</td><td>-</td><td>NM_198827:g.131487849T>G</td><td>12</td><td>131487849</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.6</td><td>-1.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>DDX11</td><td>-</td><td>NM_030653:g.31242087T>G</td><td>12</td><td>31242087</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.8</td><td>-0.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>DYRK4</td><td>-</td><td>NM_003845:g.4700466T>G</td><td>12</td><td>4700466</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-0.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>NUBPL</td><td>-</td><td>NM_025152:g.32142782T>G</td><td>14</td><td>32142782</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.1</td><td>2.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>BANP</td><td>-</td><td>NM_017869:g.88051014A>G</td><td>16</td><td>88051014</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.3</td><td>6</td><td>-2.3</td><td>rs6540151</td><td>2.1</td><td>0.041</td><td>Exonic</td><td>-2</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-2A>G </td></tr>
<tr><td>-</td><td>-</td><td>GNGT2</td><td>-</td><td>NM_031498:g.47286205T>G</td><td>17</td><td>47286205</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.1</td><td>2.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>C17orf80</td><td>-</td><td>NM_017941:g.71229465G>A</td><td>17</td><td>71229465</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.9</td><td>-3.9</td><td>-12.8</td><td>rs113825288</td><td>0.37</td><td>0.007</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>RBBP8</td><td>-</td><td>NM_002894:g.20529676G>A</td><td>18</td><td>20529676</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.5</td><td>5.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>CCDC93</td><td>-</td><td>NM_019044:g.118743543T>G</td><td>2</td><td>118743543</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>COBLL1</td><td>-</td><td>NM_014900:g.165600195T>G</td><td>2</td><td>165600195</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.7</td><td>-0.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>ANKRD36B</td><td>-</td><td>NM_025190:g.98177124A>C</td><td>2</td><td>98177124</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.3</td><td>5.2</td><td>-3.1</td><td>rs11681640</td><td>34.8</td><td>0.452</td><td>Intronic</td><td>3</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor3A>C </td></tr>
<tr><td>-</td><td>-</td><td>C20orf43</td><td>-</td><td>NM_016407:g.55045807G>A</td><td>20</td><td>55045807</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>4.7</td><td>1.7</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>MYLK</td><td>-</td><td>NM_053025:g.123554710G>A</td><td>3</td><td>123554710</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.8</td><td>6.3</td><td>-3.5</td><td>rs144796555</td><td>0.37</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>POC1A</td><td>-</td><td>NM_015426:g.52181002T>G</td><td>3</td><td>52181002</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.8</td><td>1.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>ABLIM3</td><td>-</td><td>NM_014945:g.148630982G>A</td><td>5</td><td>148630982</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.6</td><td>8.5</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>WDR46</td><td>-</td><td>NM_005452:g.33256579T>G</td><td>6</td><td>33256579</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.9</td><td>-0.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>RARS2</td><td>-</td><td>NM_020320:g.88224673T>G</td><td>6</td><td>88224673</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.7</td><td>-2.5</td><td>-8.2</td><td>rs77773960</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>METTL2B</td><td>-</td><td>NM_018396:g.128117227G>A</td><td>7</td><td>128117227</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.2</td><td>4.1</td><td>-3.1</td><td>rs76349929</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>AC007276.5.1</td><td>-</td><td>N/A:g.29700059G>T</td><td>7</td><td>29700059</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>7.6</td><td>-3.3</td><td>rs74896403</td><td>-</td><td>-</td><td>Exonic</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor-1G>T </td></tr>
<tr><td>-</td><td>-</td><td>RRM2B</td><td>-</td><td>NM_015713:g.103250667T>G</td><td>8</td><td>103250667</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>4.6</td><td>-3.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>C8orf59</td><td>-</td><td>NM_016018:g.86131463T>A</td><td>8</td><td>86131463</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-0.3</td><td>-7.8</td><td>rs67573812</td><td>31.46</td><td>0.432</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>A </td></tr>
<tr><td>-</td><td>-</td><td>URM1</td><td>-</td><td>NM_030914:g.131133696T>G</td><td>9</td><td>131133696</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.8</td><td>1.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>CLCN5</td><td>-</td><td>NM_000084:g.49689926T>G</td><td>X</td><td>49689926</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8.7</td><td>0.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>PCDH11X</td><td>-</td><td>NM_032969:g.91518144T>G</td><td>X</td><td>91518144</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.8</td><td>2.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>PAH</td><td>-</td><td>NM_000277:IVS2+1G>A</td><td>12</td><td>103310848</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.7</td><td>-2.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>DHCR7</td><td>-</td><td>NM_001360:c.321G>C</td><td>11</td><td>71155039</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.5</td><td>2.5</td><td>-4</td><td>rs104886040</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor-1G>C </td></tr>
<tr><td>-</td><td>-</td><td>AGL</td><td>-</td><td>NM_000642:IVS21+1G>A</td><td>1</td><td>100353665</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.2</td><td>-1.6</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>FBNI (FBN1)</td><td>-</td><td>NM_000138:c.344C>G</td><td>15</td><td>48902927</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.4</td><td>6.3</td><td>-1.2</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-3</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor-3C>G </td></tr>
<tr><td>-</td><td>-</td><td>NFI (NF1)</td><td>-</td><td>NM_000267:c.5546G>A</td><td>17</td><td>29654857</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>NFI (NF1)</td><td>-</td><td>NM_000267:c.6858G>C</td><td>17</td><td>29665823</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.7</td><td>4.6</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor-1G>C </td></tr>
<tr><td>-</td><td>-</td><td>MSH2</td><td>-</td><td>NM_000251:IVS5+3A>T</td><td>2</td><td>47641560</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.1</td><td>-4.5</td><td>rs193922376</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor2A>T </td></tr>
<tr><td>-</td><td>-</td><td>ARX</td><td>-</td><td>NM_139058:c.196+2T>C</td><td>X</td><td>25033657</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.4</td><td>3.9</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>ARX</td><td>-</td><td>NM_139058:c.1119+1G>C</td><td>X</td><td>25028376</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.4</td><td>0.6</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>ORC2L</td><td>-</td><td>NM_006190:g.201784944G>C</td><td>2</td><td>201784944</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.4</td><td>1.5</td><td>-9.8</td><td>rs2307356</td><td>0.26</td><td>0.005</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>GSTA2</td><td>-</td><td>NM_000846:g.52617650T>G</td><td>6</td><td>52617650</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.9</td><td>1.7</td><td>-8.2</td><td>rs2234733</td><td>1.06</td><td>0.021</td><td>Intronic</td><td>1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>donor1T>G </td></tr>
<tr><td>-</td><td>-</td><td>ADA</td><td>-</td><td>NM_000022:c.478+6T>A</td><td>20</td><td>43254204</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.3</td><td>5.7</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor5T>A </td></tr>
<tr><td>-</td><td>-</td><td>ADA</td><td>-</td><td>NM_000022:c.975+1G>A</td><td>20</td><td>43249658</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>10.6</td><td>-2.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.212+1G>A</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6</td><td>-6.8</td><td>-12.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.5340+1G>A</td><td>17</td><td>41209068</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-5.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.441+1G>A</td><td>17</td><td>41256138</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>3.7</td><td>-9.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic </td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.134+3A>C</td><td>17</td><td>41267740</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>4.4</td><td>-4.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor2A>C </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.5256+5A>G</td><td>17</td><td>41215345</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11.6</td><td>8.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.212+3A>G</td><td>17</td><td>41258470</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>5.6</td><td>-0.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor2A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA2</td><td>-</td><td>NM_000059:c.631+3A>G</td><td>13</td><td>32900753</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.6</td><td>5.2</td><td>-0.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor2A>G </td></tr>
<tr><td>-</td><td>-</td><td>CDKN2A</td><td>-</td><td>NM_000077:c.457+1G>T</td><td>9</td><td>21970900</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.1</td><td>3.3</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>CTNS</td><td>-</td><td>NM_004937:c.61+5G>A </td><td>17</td><td>3543566</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.9</td><td>5.4</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4G>A </td></tr>
<tr><td>-</td><td>-</td><td>EVC</td><td>-</td><td>NM_153717:c.1886+5G>T </td><td>4</td><td>5795449</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.8</td><td>2.9</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4G>T </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.92+5G>T </td><td>11</td><td>5248155</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>1.7</td><td>-3.9</td><td>rs33915217</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4G>T </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.92+5G>C</td><td>11</td><td>5248155</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>1.7</td><td>-3.9</td><td>rs33915217</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4G>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.92+6T>C</td><td>11</td><td>5248154</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>4.2</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor5T>C </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.92+1G>A</td><td>11</td><td>5248159</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>-7.1</td><td>-12.8</td><td>rs33971440</td><td>0.04</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>MYBPC3b</td><td>-</td><td>NM_000256:g.47369974G>A</td><td>11</td><td>7369974</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>-3.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>PITX2</td><td>-</td><td>NM_153427:c.252+5G>C</td><td>4</td><td>111542315</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6.7</td><td>2.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Total intron retention</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor4G>C </td></tr>
<tr><td>-</td><td>-</td><td>GATA1</td><td>-</td><td>NM_002049:c.220G>C</td><td>X</td><td>48649736</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8.6</td><td>4.5</td><td>-4</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Leaky</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor-1G>C </td></tr>
<tr><td>-</td><td>-</td><td>F7</td><td>-</td><td>NM_019616:c.615+1G>T</td><td>13</td><td>113771190</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>11.3</td><td>3.5</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>PCCB</td><td>-</td><td>NM_000532:c.183+2T>C</td><td>3</td><td>135969402</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>6.8</td><td>-0.7</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor1T>C </td></tr>
<tr><td>-</td><td>-</td><td>PCCB</td><td>-</td><td>NM_000532:c.653A>G</td><td>3</td><td>136002788</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>11</td><td>8.7</td><td>-2.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-2</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor-2A>G </td></tr>
<tr><td>-</td><td>-</td><td>PCCB</td><td>-</td><td>NM_000532:c.653A>G</td><td>3</td><td>136002788</td><td>Cryptic</td><td>DONOR</td><td>Strengthened</td><td>6.1</td><td>9.6</td><td>3.5</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-6</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor-6A>G </td></tr>
<tr><td>-</td><td>-</td><td>RHO</td><td>-</td><td>NM_000539:c.936G>A</td><td>11</td><td>129251615</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.3</td><td>2.3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Leaky and Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor-1G>A </td></tr>
<tr><td>-</td><td>-</td><td>RHO</td><td>-</td><td>NM_000539:c.936G>A</td><td>11</td><td>129251615</td><td>Cryptic</td><td>DONOR</td><td>Created</td><td>0</td><td>2.6</td><td>2.6</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-4</td><td>Y</td><td>Leaky and Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>donor-4G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.212+3A>G (IVS5)</td><td>17</td><td>41258470</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>5.6</td><td>-0.4</td><td>rs80358083</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>donor2A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.212+1G>A (IVS5)</td><td>17</td><td>41258472</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>6</td><td>-6.8</td><td>-12.8</td><td>rs80358042</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.5277+1G>A (IVS20)</td><td>17</td><td>41209068</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>-5.2</td><td>-12.8</td><td>rs80358150</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>donor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.134+3A>C (IVS3)</td><td>17</td><td>41267740</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.1</td><td>4.4</td><td>-4.8</td><td>rs80358064</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>donor2A>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1+1G>T</td><td>X</td><td>133594369</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1+2T>A</td><td>X</td><td>133594370</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1+5G>A</td><td>X</td><td>133594373</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1+5G>T</td><td>X</td><td>133594373</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS2+1G>A</td><td>X</td><td>133607496</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>12.7</td><td>-0.1</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS2+2T>G</td><td>X</td><td>133607497</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.7</td><td>4.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3+1G>A</td><td>X</td><td>133609395</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.1</td><td>-7.7</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3+1G>T</td><td>X</td><td>133609395</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>5.1</td><td>-2.7</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4+1G>A</td><td>X</td><td>133620561</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>-3.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4+1G>T</td><td>X</td><td>133620561</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.7</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4+2T>G</td><td>X</td><td>133620562</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4+2T>A</td><td>X</td><td>133620562</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.7</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+1G>A</td><td>X</td><td>133624236</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-4.8</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+1G>T</td><td>X</td><td>133624236</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+2T>G</td><td>X</td><td>133624237</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>-0.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+2T>A</td><td>X</td><td>133624237</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+2T>C</td><td>X</td><td>133624237</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>8</td><td>0.5</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+5G>A</td><td>X</td><td>133624240</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8</td><td>4.5</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5+5G>T</td><td>X</td><td>133624240</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>8</td><td>4.1</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6+1G>A</td><td>X</td><td>133627621</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>-3.3</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6+1G>T</td><td>X</td><td>133627621</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.7</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6+2T>G</td><td>X</td><td>133627622</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6+2T>C</td><td>X</td><td>133627622</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>2</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6+2T>A</td><td>X</td><td>133627622</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.5</td><td>1.7</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+1G>A</td><td>X</td><td>133632467</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-5.2</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+1G>T</td><td>X</td><td>133632467</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+2T>C</td><td>X</td><td>133632468</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>0.2</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+2T>A</td><td>X</td><td>133632468</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.6</td><td>-0.2</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+3A>T</td><td>X</td><td>133632469</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.1</td><td>-4.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor2A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+5G>C</td><td>X</td><td>133632471</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+5G>A</td><td>X</td><td>133632471</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.1</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+5G>T</td><td>X</td><td>133632471</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>3.7</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7+6T>C</td><td>X</td><td>133632472</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>6.2</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor5T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+1G>C</td><td>X</td><td>133632715</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>-0.5</td><td>-9.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+1G>A</td><td>X</td><td>133632715</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>-3.5</td><td>-12.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+1G>T</td><td>X</td><td>133632715</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>1.5</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+2T>G</td><td>X</td><td>133632716</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>1.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+2T>C</td><td>X</td><td>133632716</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>1.8</td><td>-7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+2T>A</td><td>X</td><td>133632716</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>9.3</td><td>1.5</td><td>-7.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor1T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+3A>T</td><td>X</td><td>133632717</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>4.8</td><td>-4.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>2</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor2A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+4A>G</td><td>X</td><td>133632718</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>6.7</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor3A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+5G>C</td><td>X</td><td>133632719</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>5.3</td><td>-3.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+5G>A</td><td>X</td><td>133632719</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>5.7</td><td>-3.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>4</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor4G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+6T>G</td><td>X</td><td>133632720</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>8</td><td>-1.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor5T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+6T>C</td><td>X</td><td>133632720</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>7.8</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor5T>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8+6T>A</td><td>X</td><td>133632720</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.3</td><td>7.7</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>5</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor5T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133594368G>A</td><td>X</td><td>133594368</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627620G>A</td><td>X</td><td>133627620</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627620G>T</td><td>X</td><td>133627620</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.2</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133594368G>A</td><td>X</td><td>133594368</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133594368G>T</td><td>X</td><td>133594368</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>7.6</td><td>4.3</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133607495G>A</td><td>X</td><td>133607495</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.8</td><td>9.7</td><td>-3.1</td><td>rs137852491</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133607495G>T</td><td>X</td><td>133607495</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>12.8</td><td>9.4</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133620560G>A</td><td>X</td><td>133620560</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.2</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133620560G>T</td><td>X</td><td>133620560</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627620G>A</td><td>X</td><td>133627620</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.2</td><td>-3.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627620G>T</td><td>X</td><td>133627620</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>9.5</td><td>6.4</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>donor-1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>TMTC2</td><td>Autosomal Dominant</td><td>NM_152588:g.83359523G>A</td><td>12</td><td>83359523</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>2.2</td><td>-0.8</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>-1</td><td>Y</td><td>Skipping and intron inclusion</td><td>Viner C. F1000Res. 2014;3:8-8.v2.</td><td>donor-1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4986+4A>T (IVS16)</td><td>17</td><td>41222941</td><td>Natural</td><td>DONOR</td><td>Weakened</td><td>5.7</td><td>2.6</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor3A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.475+1G>T (IVS5)</td><td>13</td><td>32900288</td><td>Natural</td><td>DONOR</td><td>Abolished</td><td>7.5</td><td>-0.3</td><td>-7.8</td><td>rs81002797</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>donor0G>T </td></tr>
<tr><td>Xeroderma pigmentosum</td><td>  <1 / 1 000 000</td><td>XPC</td><td>autosomal recessive</td><td>NM_004628:c.413-9T>A</td><td>3</td><td>14209889</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>-0.1</td><td>-2.3</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-8</td><td>Y</td><td>Skipping</td><td>Khan SG. Hum Mol Genet. 2004;13(3):343-352</td><td>acceptor-8T>A </td></tr>
<tr><td>Xeroderma pigmentosum</td><td>  <1 / 1 000 000</td><td>XPC</td><td>autosomal recessive</td><td>NM_004628:c.413-24A>G</td><td>3</td><td>14209904</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>-0.1</td><td>-0.4</td><td>-0.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-23</td><td>Y</td><td>Leaky</td><td>Khan SG. Hum Mol Genet. 2004;13(3):343-352</td><td>acceptor-23A>G </td></tr>
<tr><td>Xeroderma pigmentosum</td><td>  <1 / 1 000 000</td><td>XPC</td><td>autosomal recessive</td><td>NM_004628:c.2251-6C>A</td><td>3</td><td>14190237</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.5</td><td>5.1</td><td>-2.5</td><td>rs2279017</td><td>35.57</td><td>0.452</td><td>Intronic</td><td>-5</td><td>Y</td><td>Increased skipping</td><td>Khan SG. Nucleic Acids Res. 2002;30(16):3624-3631</td><td>acceptor-5C>A </td></tr>
<tr><td>Hereditary spastic paraplegia (SG31)</td><td>unknown</td><td>REEP1</td><td>autosomal dominant</td><td>NM_022912:c.182-2A>G</td><td>2</td><td>86491166</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.3</td><td>2.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Beetz C. Brain. 2008;131(Pt 4):1078-1086</td><td>acceptor-1A>G </td></tr>
<tr><td>Carpenter syndrome</td><td>  <1 / 1 000 000</td><td>RAB23</td><td>autosomal recessive</td><td>NM_016277:c.482-1G>A</td><td>6</td><td>57058733</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10</td><td>2.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Ben-Salem S. Mol Syndromol. 2013;3(6):255-261</td><td>acceptor0G>A </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.454-2A>G</td><td>X</td><td>103042725</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.2</td><td>-5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Bonnet-Dupeyron MN. Hum Mutat. 2008;29(8):1028-1036</td><td>acceptor-1A>G </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.454-1G>T</td><td>X</td><td>103042726</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.2</td><td>-5.6</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Bonnet-Dupeyron MN. Hum Mutat. 2008;29(8):1028-1036</td><td>acceptor0G>T </td></tr>
<tr><td>Pelizaeus-Merzbacher disease</td><td>1-9 / 1 000 000</td><td>PLP1</td><td>X-linked recessive X-linked dominant</td><td>NM_000533:c.454-1G>A</td><td>X</td><td>103042726</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.2</td><td>-4.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Bonnet-Dupeyron MN. Hum Mutat. 2008;29(8):1028-1036</td><td>acceptor0G>A </td></tr>
<tr><td>Netherton Syndrome</td><td>1/200 000 newborns<sup>2</sup></td><td>SPINK5</td><td>autosomal recessive</td><td>NM_006846:c.283-12T>A</td><td>5</td><td>147465956</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.2</td><td>6.6</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-11</td><td>Y</td><td>Cryptic (retention)</td><td>Lacroix M. J Invest Dermatol. 2011</td><td>acceptor-11T>A </td></tr>
<tr><td>Netherton Syndrome</td><td>1/200 000 newborns<sup>2</sup></td><td>SPINK5</td><td>autosomal recessive</td><td>NM_006846:c.283-12T>A</td><td>5</td><td>147465956</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.5</td><td>1.9</td><td>7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-10</td><td>Y</td><td>Cryptic (retention)</td><td>Lacroix M. J Invest Dermatol. 2011</td><td>acceptor-10T>A </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS7-1G>A</td><td>X</td><td>48546442</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.4</td><td>2.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>acceptor0G>A </td></tr>
<tr><td>Wiskott-Aldrich syndrome </td><td>4/million in China</td><td>WAS</td><td>X-linked recessive</td><td>NM_000377:IVS7-1G>A</td><td>X</td><td>48546442</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3</td><td>5.1</td><td>8.1</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>Lee PP. J Clin Immunol. 2009;29(4):490-500.</td><td>acceptor1G>A </td></tr>
<tr><td>Frontotemporal lobar degeneration</td><td>  1-9 / 100 000</td><td>GRN</td><td>autosomal dominant</td><td>NM_002087:c.709-2A>G</td><td>17</td><td>42428403</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.8</td><td>-0.4</td><td>-8.2</td><td>rs63750548</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Leverenz JB.Brain. 2007;130(Pt 5):1360-1374</td><td>acceptor-1A>G </td></tr>
<tr><td>Kindler syndrome</td><td>unknown</td><td>FERMT1</td><td>autosomal recessive</td><td>NM_017671:IVS9-6T>A</td><td>20</td><td>6069742</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9</td><td>6.3</td><td>-2.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>Y</td><td>Skipping</td><td>Arita K. Br J Dermatol. 2007;157(6):1252-1256</td><td>acceptor-5T>A </td></tr>
<tr><td>Xeroderma pigmentosum</td><td>  <1 / 1 000 000</td><td>XPC</td><td>autosomal recessive</td><td>NM_004628:IVS12-1G>C</td><td>3</td><td>14190232</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.1</td><td>-2.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>Cartault F. 2011;10(6):577-585</td><td>acceptor0G>C </td></tr>
<tr><td>Bietti crystalline corneoretinal dystrophy</td><td>unknown</td><td>CYP4V2</td><td>autosomal recessive</td><td>NM_207352:IVS2-1G>A</td><td>4</td><td>187117156</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10</td><td>2.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Li A. The American Journal of Human Genetics. 2004;74(5):817-826.</td><td>acceptor0G>A </td></tr>
<tr><td>Bietti crystalline corneoretinal dystrophy</td><td>unknown</td><td>CYP4V2</td><td>autosomal recessive</td><td>NM_207352:IVS2-1G>A</td><td>4</td><td>187117156</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-0.5</td><td>7.7</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Li A. The American Journal of Human Genetics. 2004;74(5):817-826.</td><td>acceptor1G>A </td></tr>
<tr><td>Bietti crystalline corneoretinal dystrophy</td><td>unknown</td><td>CYP4V2</td><td>autosomal recessive</td><td>NM_207352:IVS8-2A>G</td><td>4</td><td>187130017</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.5</td><td>2.3</td><td>-8.2</td><td>rs199476183</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Li A. The American Journal of Human Genetics. 2004;74(5):817-826.</td><td>acceptor-1A>G </td></tr>
<tr><td>Keratoconus</td><td>50-230/100 000</td><td>VSX1</td><td>autosomal dominant</td><td>NM_014588:c.844-13T>A</td><td>20</td><td>25057199</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.4</td><td>10</td><td>-2.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>N</td><td>-</td><td>Dash DP. Eye (Lond). 2010;24(6):1085-1092</td><td>acceptor-12T>A </td></tr>
<tr><td>Drug metabolism</td><td>-</td><td>GSTM4</td><td>-</td><td>NM_000850:c.260-2A>T</td><td>1</td><td>110200392</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.1</td><td>-4.3</td><td>-7.4</td><td>rs146365598</td><td>0.06</td><td>0.002</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Denson J. Gene. 2006;379:148-155</td><td>acceptor-1A>T </td></tr>
<tr><td>Juvenile-onset primary lateral sclerosis</td><td><1 / 1 000 000</td><td>ALS2</td><td>autosomal recessive</td><td>NM_020919:c.2980-2A>G</td><td>2</td><td>202591591</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.5</td><td>0.3</td><td>-8.2</td><td>rs386134184</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Mintchev N. Neurology. 2009;72(1):28-32.</td><td>acceptor-1A>G </td></tr>
<tr><td>Dopa responsive dystonia</td><td>0.5-1.0/1 000 000</td><td>GCH1</td><td>autosomal dominant</td><td>NM_000161:IVS5-6T>G</td><td>14</td><td>55310867</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.1</td><td>6.2</td><td>-2.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>N</td><td>-</td><td>Naiya T. J Neural Transm. 2012.</td><td>acceptor-5T>G </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.3843-2A>G</td><td>2</td><td>21236407</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.1</td><td>0.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Di Leo E. J Med Genet. 2007;44(3):219-224</td><td>acceptor-1A>G </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.4217-1G>T</td><td>2</td><td>21235524</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.7</td><td>0</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Di Leo E. J Med Genet. 2007;44(3):219-224</td><td>acceptor0G>T </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.1471-1G>A</td><td>2</td><td>21252658</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.6</td><td>6</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention and deletion)</td><td>Di Leo E. Mol Genet Metab. 2009;96(2):66-72.</td><td>acceptor0G>A </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.1471-1G>A</td><td>2</td><td>21252658</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3.6</td><td>4.6</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Cryptic (retention and deletion)</td><td>Di Leo E. Mol Genet Metab. 2009;96(2):66-72.</td><td>acceptor1G>A </td></tr>
<tr><td>Familial hypobetalipidemia</td><td>1/1000-3000</td><td>APOB</td><td>codominant</td><td>NM_000384:c.3697-1G>C</td><td>2</td><td>21237466</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.9</td><td>1.6</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Di Leo E. Mol Genet Metab. 2009;96(2):66-72.</td><td>acceptor0G>C </td></tr>
<tr><td>Familial hypobetalipoproteinemia</td><td>1:500 (world) 1:165 (Tunisea)</td><td>MTTP</td><td>codominant</td><td>NM_000384:c.619-3T>G</td><td>4</td><td>100512805</td><td>Natural</td><td>Acceptor</td><td>Abolished</td><td>4.9</td><td>0.6</td><td>-4.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Skipping</td><td>Najah M. Clin Chim Acta. 2009;401(1-2):51-56.</td><td>acceptor-2T>G </td></tr>
<tr><td>Hereditary pulmonary arterial hypertension</td><td>unknown</td><td>SMAD4</td><td>autosomal dominant</td><td>NM_005359:c.1448-6T>C</td><td>18</td><td>48604620</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.1</td><td>6.9</td><td>-0.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>Y</td><td>Lower transcript levels</td><td>Nasim MT. Hum Mutat. 2011;32(12):1385-1389.</td><td>acceptor-5T>C </td></tr>
<tr><td>Xeroderma pigmentosum variant B</td><td>  <1 / 1 000 000</td><td>ERCC3</td><td>autosomal recessive</td><td>NM_000122:c.2218-6C>A</td><td>2</td><td>128015309</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.5</td><td>6</td><td>-2.5</td><td>rs200733704</td><td>0.05</td><td>0.001</td><td>Intronic</td><td>-5</td><td>Y</td><td>Increased cryptic</td><td>Oh KS. Hum Mutat. 2006;27(11):1092-1103</td><td>acceptor-5C>A </td></tr>
<tr><td>Xeroderma pigmentosum variant B</td><td>  <1 / 1 000 000</td><td>ERCC3</td><td>autosomal recessive</td><td>NM_000122:c.2218-6C>A</td><td>2</td><td>128015309</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.8</td><td>10.2</td><td>7.4</td><td>rs200733704</td><td>0.05</td><td>0.001</td><td>Intronic</td><td>-4</td><td>Y</td><td>Increased cryptic</td><td>Oh KS. Hum Mutat. 2006;27(11):1092-1103</td><td>acceptor-4C>A </td></tr>
<tr><td>Dystrophic epidermolysis bullosa</td><td>1-9 / 100 000</td><td>COL7A1</td><td>autosomal recessive</td><td>NM_000094:c.1094-1G>C</td><td>3</td><td>48629682</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.5</td><td>2.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Oh SW. Br J Dermatol. 2007;157(6):1260-1264.</td><td>acceptor0G>C </td></tr>
<tr><td>Leukocyte adhesion deficiency III</td><td><1 / 1 000 000</td><td>RASGRP2</td><td>autosomal recessive</td><td>NM_0058250:c.718C>A (NM_153819:c.1592-3C>A)</td><td>11</td><td>64496517</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>6.1</td><td>-4.2</td><td>rs75902820</td><td>2.31</td><td>0.033</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Pasvolsky R. J Exp Med. 2007;204(7):1571-1582</td><td>acceptor-2C>A </td></tr>
<tr><td>Leukocyte adhesion deficiency III</td><td><1 / 1 000 000</td><td>RASGRP2</td><td>autosomal recessive</td><td>NM_0058250:c.718C>A (NM_153819:c.1592-3C>A)</td><td>11</td><td>64496517</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3.6</td><td>3.9</td><td>7.5</td><td>rs75902820</td><td>2.31</td><td>0.033</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Pasvolsky R. J Exp Med. 2007;204(7):1571-1582</td><td>acceptor-1C>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS1-2A>G</td><td>22</td><td>30032738</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.7</td><td>2.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-584</td><td>acceptor-1A>G </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>T</td><td>22</td><td>30050645</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.2</td><td>6.4</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-585</td><td>acceptor0G>T </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>T</td><td>22</td><td>30050645</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>2</td><td>4.9</td><td>2.9</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>5</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-585</td><td>acceptor5G>T </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>T</td><td>22</td><td>30050645</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>0.7</td><td>1.9</td><td>1.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>20</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-585</td><td>acceptor20G>T </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>A</td><td>22</td><td>30050645</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.2</td><td>7.6</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-586</td><td>acceptor0G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>A</td><td>22</td><td>30050645</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>0.7</td><td>1</td><td>0.3</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>20</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-585</td><td>acceptor20G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-1G>A</td><td>22</td><td>30050645</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2</td><td>2.2</td><td>0.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>5</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-585</td><td>acceptor5G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-2A>G</td><td>22</td><td>30050644</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.2</td><td>7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-1A>G </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS4-2A>G</td><td>22</td><td>30050644</td><td>Cryptic</td><td>ACCEPTOR</td><td>Weakened</td><td>0.7</td><td>0</td><td>-0.7</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>20</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor20A>G </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS11-2A>C</td><td>22</td><td>30069256</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5</td><td>-2.4</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (retention)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-1A>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS11-2A>G</td><td>22</td><td>30069256</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5</td><td>-3.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (retention)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-1A>G </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS12-2A>C</td><td>22</td><td>30070823</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>6.6</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-1A>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS12-2A>C</td><td>22</td><td>30070823</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>1.4</td><td>3.4</td><td>2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>8</td><td>Y</td><td>Cryptic (deletion)</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor8A>C </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS12-1G>A</td><td>22</td><td>30070824</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>14</td><td>6.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Normal splicing</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor0G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS13-1G>A</td><td>22</td><td>30077427</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.9</td><td>-2.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor0G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS13-1G>T</td><td>22</td><td>30077427</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.9</td><td>-3.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor0G>T </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS13-2A>G</td><td>22</td><td>30077426</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.9</td><td>-3.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-1A>G </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS14-1G>A</td><td>22</td><td>30077427</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.4</td><td>-2.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor0G>A </td></tr>
<tr><td>Neurofibromatosis type 2</td><td>1-9 / 100 000</td><td>NF2</td><td>autosomal dominant</td><td>NM_000268:IVS14-3C>G</td><td>22</td><td>30077425</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.4</td><td>-0.6</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Skipping</td><td>Ellis JR. Genes Chromosomes Cancer. 2011;50(8):571-587</td><td>acceptor-2C>G </td></tr>
<tr><td>Junctional epiderdermolysis bullosa</td><td>  <1 / 1 000 000</td><td>LAMB3</td><td>autosomal recessive</td><td>NM_000228:c.629-1G>A</td><td>1</td><td>209806122</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.5</td><td>2.9</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Increased cryptic (deletion)</td><td>Pasmooij AM. J Clin Invest. 2007;117(5):1240-1248</td><td>acceptor0G>A </td></tr>
<tr><td>High cholesterol</td><td>very common</td><td>ABCA1</td><td>multifactorial</td><td>NM_005502:IVS31-1G>C</td><td>9</td><td>107567002</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.4</td><td>-3.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>Rhyne J. BMC Med Genet. 2009;10:1.</td><td>acceptor0G>C </td></tr>
<tr><td>Catecholaminergic polymorphic ventricular tachycardia (CPVY) </td><td>1/10 000</td><td>CASQ2</td><td>autosomal recessive</td><td>NM_001232:c.320-2A>G</td><td>1</td><td>116283451</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.9</td><td>5.8</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Roux-Buisson N. Hum Mutat. 2011</td><td>acceptor-1A>G </td></tr>
<tr><td>Cortisol resistance</td><td>-</td><td>NR3C1</td><td>autosomal recessive</td><td>NM_001018076:c.2182-9C>G</td><td>5</td><td>142661615</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.2</td><td>11.6</td><td>-1.6</td><td>rs72542757</td><td>0.81</td><td>0.015</td><td>Intronic</td><td>-8</td><td>Y</td><td>Cryptic</td><td>Russcher H. J Clin Endocrinol Metab. 2006;91(2):694-701</td><td>acceptor-8C>G </td></tr>
<tr><td>Inherited Obesity</td><td>unknown</td><td>LEPR</td><td>autosomal dominant</td><td>NM_002303:c.2396-1G>T</td><td>1</td><td>66085610</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13</td><td>4.3</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Saeed S. Obesity. 2014; 22(4):1112-7</td><td>acceptor0G>T </td></tr>
<tr><td>Inherited Obesity</td><td>unknown</td><td>LEPR</td><td>autosomal dominant</td><td>NM_002303:c.2396-1G>T</td><td>1</td><td>66085610</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3.4</td><td>4.6</td><td>1.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>20</td><td>N</td><td>-</td><td>Saeed S. Obesity. 2014; 22(4):1112-7</td><td>acceptor20G>T </td></tr>
<tr><td>Inherited Obesity</td><td>unknown</td><td>LEPR</td><td>autosomal dominant</td><td>NM_002303:c.2396-1G>T</td><td>1</td><td>66085610</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-1.3</td><td>3</td><td>4.3</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>2</td><td>N</td><td>-</td><td>Saeed S. Obesity. 2014; 22(4):1112-7</td><td>acceptor2G>T </td></tr>
<tr><td>Type 4 Waardenburg syndrome </td><td><1 / 1 000 000</td><td>SOX10</td><td>autosomal dominant</td><td>NM_006941:c.698-2A>C</td><td>22</td><td>38370207</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.8</td><td>6.4</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Sznajer Y. Am J Med Genet A. 2008;146A(8):1038-1041</td><td>acceptor-1A>C </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>NM_000084:IVS3-1G>A</td><td>X</td><td>49840449</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8</td><td>0.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Tosetto E.Nephrol Dial Transplant. 2006;21(9):2452-2463</td><td>acceptor0G>A </td></tr>
<tr><td>Dent disease type 1</td><td>unknown</td><td>CLCN5</td><td>X-linked</td><td>NM_000084:IVS2-17T>G</td><td>X</td><td>49837127</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.2</td><td>10.9</td><td>-1.4</td><td>rs56117808</td><td>0.24</td><td>0.005</td><td>Intronic</td><td>-16</td><td>Y</td><td>Skipping</td><td>Tosetto E.Nephrol Dial Transplant. 2006;21(9):2452-2463</td><td>acceptor-16T>G </td></tr>
<tr><td>Aniridia</td><td>1-9 / 100 000</td><td>PAX6</td><td>autosomal dominant</td><td>NM_001604:c.184-3C>G</td><td>11</td><td>31823327</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.3</td><td>6.3</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Wang P. Mol Vis. 2006;12:644-648</td><td>acceptor-2C>G </td></tr>
<tr><td>Smith-Lemli-Opitz syndrome</td><td>1/60 000 (USA)</td><td>DHCR7</td><td>autosomal recessive</td><td>NM_001163817:IVS8-1G>C</td><td>11</td><td>71146886</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.5</td><td>6.2</td><td>-7.3</td><td>rs138659167</td><td>0.47</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Yu H. Clin Genet. 2005;68(5):383-391.</td><td>acceptor0G>C </td></tr>
<tr><td>Ectopia lentis</td><td><1 / 1 000 000</td><td>FBN1</td><td>autosomal dominant</td><td>NM_000138:IVS18-1G>T</td><td>15</td><td>48789589</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>0.5</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Zhao L. Mol Vis. 2009;15:826-832</td><td>acceptor0G>T </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:IVS4-2A>G</td><td>18</td><td>28909853</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.1</td><td>7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>acceptor-1A>G </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:IVS4-2A>G</td><td>18</td><td>28909853</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>1</td><td>8.6</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>acceptor-1A>G </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:IVS9-3C>G</td><td>18</td><td>28918275</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.4</td><td>4.4</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>acceptor-2C>G </td></tr>
<tr><td>Striate palmoplantar keratoderma</td><td>unknown</td><td>DSG1</td><td>autosomal dominant</td><td>NM_001942:IVS9-3C>G</td><td>18</td><td>28918275</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-0.4</td><td>6.9</td><td>7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Dua-Awereh MB. J Dermatol Sci. 2009;53(3):192-197</td><td>acceptor-2C>G </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2C9</td><td>polymorphism</td><td>NM_000771:c.332-13C>G</td><td>10</td><td>96701936</td><td>Natural</td><td>ACCEPTOR</td><td>Weakeneding</td><td>11.6</td><td>10.1</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>N</td><td>-</td><td>Xiong Y. Genomics. 2011;97(5):277-281.</td><td>acceptor-12C>G </td></tr>
<tr><td>CHARGE syndrome</td><td>>100 reported cases</td><td>CHD7</td><td>autosomal dominant</td><td>NM_017780:c.2836-1G>T</td><td>8</td><td>61734582</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>0.9</td><td>-7.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Johnson DS. University of Glasgow; 2010</td><td>acceptor0G>T </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-1G>A </td><td>7</td><td>117227792</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.1</td><td>0.5</td><td>-7.6</td><td>rs76713772</td><td>0.06</td><td>0.001</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor0G>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-1G>A </td><td>7</td><td>117227792</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.4</td><td>2.8</td><td>8.2</td><td>rs76713772</td><td>0.06</td><td>0.001</td><td>Exonic</td><td>1</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>"Sharma, N. et al. . Hum. Mutat.  (2014). "</td><td>acceptor1G>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-2A>G </td><td>7</td><td>117227791</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.1</td><td>-0.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor-1A>G </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-3T>G </td><td>7</td><td>117227790</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.1</td><td>3.8</td><td>-4.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor-2T>G </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-3T>G </td><td>7</td><td>117227790</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-4.4</td><td>4.3</td><td>8.7</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>-2</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor-2T>G </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-9T>A </td><td>7</td><td>117227784</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.1</td><td>5.9</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-8</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor-8T>A </td></tr>
<tr><td>Cystic fibrosis</td><td>  1-5 / 10 000</td><td>CFTR</td><td>autosomal recessive</td><td>NM_000492:c.1585-9T>A </td><td>7</td><td>117227784</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.6</td><td>10</td><td>7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-8</td><td>Y</td><td>Skipping and cryptic (retention)</td><td>"Sharma, N. Hum. Mutat. 35(10), 1249-1259 (2014)."</td><td>acceptor-8T>A </td></tr>
<tr><td>Autosomal recessive retinitis pigmentosum</td><td><1/3500</td><td>CRB1</td><td>autosomal recessive</td><td>NM_201253:c.2129A>T</td><td>1</td><td>197396584</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.7</td><td>5.4</td><td>-1.3</td><td>rs145282040</td><td>0.02</td><td>-</td><td>Missense</td><td>1</td><td>Y</td><td>Leaky</td><td>Clark GR. Ophthalmology. 2010;117(11):2169-77.e3</td><td>acceptor1A>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>COX15</td><td>inherited or sporadic</td><td>NM_078470:IVS3-3C>G</td><td>10</td><td>101486914</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>4</td><td>-6</td><td>rs200910834 </td><td>0.05</td><td>0.001</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-2C>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>COX15</td><td>inherited or sporadic</td><td>NM_078470:IVS3-5C>G</td><td>10</td><td>101486916</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>7.4</td><td>-2.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-4C>G </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DES</td><td>inherited or sporadic</td><td>NM_001927:IVS2-1G>A</td><td>2</td><td>220284972</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>4.4</td><td>-7.6</td><td>rs267607484</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DES</td><td>inherited or sporadic</td><td>NM_001927:IVS2-1G>A</td><td>2</td><td>220284972</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-2.2</td><td>5.9</td><td>8.1</td><td>rs267607484</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor1G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSC2</td><td>autosomal recessive or dominant</td><td>NM_024422:IVS5-2A>G</td><td>18</td><td>28667778</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.2</td><td>6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSC2</td><td>autosomal recessive or dominant</td><td>NM_024422:IVS5-2A>G</td><td>18</td><td>28667778</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>6.9</td><td>7.8</td><td>0.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-2A>G </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>DSG2</td><td>autosomal recessive or dominant</td><td>NM_001943:IVS12-2A>G</td><td>18</td><td>29121154</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.2</td><td>-2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DSP</td><td>inherited or sporadic</td><td>NM_004415:IVS3-1G>A</td><td>6</td><td>7559458</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.4</td><td>4.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>A </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>LMNA</td><td>inherited or sporadic</td><td>NM_170707:IVS1-1G>T</td><td>1</td><td>156100407</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.4</td><td>3.6</td><td>-8.7</td><td>rs267607569</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>T </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS1-2A>G</td><td>11</td><td>47373058</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.8</td><td>-2.4</td><td>-8.2</td><td>rs376395543</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS5-2A>C</td><td>11</td><td>47370094</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.4</td><td>-1.1</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS5-1G>A</td><td>11</td><td>47370093</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.4</td><td>-1.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS11-2A>G</td><td>11</td><td>47367923</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>-1.3</td><td>-9.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS14-1G>A  (was IVS15)</td><td>11</td><td>47364487</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.5</td><td>-2.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS22-2A>G</td><td>11</td><td>47359347</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.1</td><td>-3.1</td><td>-8.2</td><td>rs111729952</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS23-2A>G</td><td>11</td><td>47359132</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.7</td><td>-4.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYL2</td><td>inherited or sporadic</td><td>NM_000432:IVS5-2A>G</td><td>12</td><td>111350950</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.1</td><td>5.9</td><td>-8.2</td><td>rs199474812</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYL2</td><td>inherited or sporadic</td><td>NM_000432:IVS6-1G>C</td><td>12</td><td>111348980</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.2</td><td>-0.1</td><td>-7.3</td><td>rs199474813</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>C </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS4-2A>G</td><td>12</td><td>33003909</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.6</td><td>3.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS7-1G>C</td><td>12</td><td>32977097</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.8</td><td>4.6</td><td>-7.3</td><td>rs78897684</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>C </td></tr>
<tr><td>Lynch Syndrome</td><td>unknown</td><td>MLH1</td><td>autosomal dominant</td><td>NM_000249:c.791-5T>G</td><td>3</td><td>37058992</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.2</td><td>7.1</td><td>-3.1</td><td>rs267607788</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>Skipping</td><td>Tournier I. Hum Mutat. 2008;29(12):1412-1424</td><td>acceptor-4T>G </td></tr>
<tr><td>Tangier disease</td><td>  <1 / 1 000 000</td><td>ABCA1</td><td>autosomal recessive</td><td>NM_005502:c.2961-2A>C</td><td>9</td><td>107582352</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>1.8</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Bocchi L. Clin Chim Acta. 2010;411(7-8):524-530</td><td>acceptor-1A>C </td></tr>
<tr><td>Tangier disease</td><td>  <1 / 1 000 000</td><td>ABCA1</td><td>autosomal recessive</td><td>NM_005502:c.2961-2A>C</td><td>9</td><td>107582352</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.3</td><td>1.7</td><td>1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>14</td><td>Y</td><td>Skipping and cryptic</td><td>Bocchi L. Clin Chim Acta. 2010;411(7-8):524-530</td><td>acceptor14A>C </td></tr>
<tr><td>Trichothiodystrophy</td><td>unknown - rare</td><td>ERCC2</td><td>autosomal recessive</td><td>NM_000400:c.950-3C>A</td><td>19</td><td>45867172</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.7</td><td>2.5</td><td>-4.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Leaky</td><td>Botta E. Hum Mutat. 2009;30(3):438-445</td><td>acceptor-2C>A </td></tr>
<tr><td>Glucocorticoid sensitivity</td><td>N/A</td><td>NR3C1</td><td>N/A</td><td>NM_001018077:c.2182-9C>G</td><td>5</td><td>142661615</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.2</td><td>11.6</td><td>-1.6</td><td>rs72542757</td><td>0.81</td><td>0.015</td><td>Intronic</td><td>-8</td><td>Y</td><td>Increased cryptic</td><td>"Smit P. Rotterdam, Netherlands: Erasmus University; 2006"</td><td>acceptor-8C>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5002</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:IVS4-2A>G</td><td>X</td><td>154215582</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.7</td><td>4.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>-</td><td>vonKodolitsch Hemophilia 12:258-64</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5003</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:c.144-1G>A</td><td>X</td><td>154227876</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.1</td><td>5.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (low)</td><td>vonKodolitsch Hemophilia 12:258-65</td><td>acceptor0G>A </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5004</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:c.671-2A>G</td><td>X</td><td>154213080</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>5.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (low)</td><td>vonKodolitsch Hemophilia 12:258-66</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5004</td><td>F8C(F8)</td><td>X-linked recessive </td><td>NM_000132:c.671-2A>G</td><td>X</td><td>154213080</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>5.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (low)</td><td>vonKodolitsch Hemophilia 12:258-66</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5004</td><td>F8C (F8)</td><td>X-linked recessive </td><td>NM_000132:c.671-2A>G</td><td>X</td><td>154213080</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-0.8</td><td>6.8</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (low)</td><td>vonKodolitsch Hemophilia 12:258-66</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia A </td><td> 1/4000-1/5005</td><td>F8C</td><td>X-linked recessive </td><td>NM_000132:c.788-1G>C</td><td>X</td><td>154197828</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.4</td><td>4.1</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (low)</td><td>vonKodolitsch Hemophilia 12:258-67</td><td>acceptor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2-3T>G</td><td>X</td><td>138619518</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.5</td><td>8.2</td><td>-4.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Reduced transcript levels (moderate)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-2T>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2-3T>G</td><td>X</td><td>138619518</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>4.4</td><td>13.1</td><td>8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Reduced transcript levels (moderate)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-2T>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3-1G>A</td><td>X</td><td>138623234</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.3</td><td>-2.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>C</td><td>X</td><td>138630520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.8</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3</td><td>4.5</td><td>7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2-1G>C</td><td>X</td><td>138619520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.5</td><td>5.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.2</td><td>6.2</td><td>6</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>2</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor2G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1-1G>A</td><td>X</td><td>138619168</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.3</td><td>0.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1-1G>T</td><td>X</td><td>138619168</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.3</td><td>-0.5</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS1-1G>T</td><td>X</td><td>138619168</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.5</td><td>4.7</td><td>2.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>9</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor9G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS2-1G>A</td><td>X</td><td>138619520</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.5</td><td>4.9</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3-3A>G</td><td>X</td><td>138623232</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.3</td><td>3.5</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-2A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3-3A>G</td><td>X</td><td>138623232</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-0.5</td><td>7</td><td>7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-2A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3-2A>T</td><td>X</td><td>138623233</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.3</td><td>-2.2</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS3-1G>T</td><td>X</td><td>138623234</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.3</td><td>-3.5</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3</td><td>4.5</td><td>7.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-2A>T</td><td>X</td><td>138630520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.8</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.2</td><td>6.2</td><td>6</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>2</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor2G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>T</td><td>X</td><td>138630521</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>2.4</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-1G>T</td><td>X</td><td>138630521</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.2</td><td>4.5</td><td>4.3</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>2</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor2G>T </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS4-4T>C</td><td>X</td><td>138630518</td><td>Natural</td><td>ACCEPTOR</td><td>Insignificant</td><td>11.2</td><td>11.5</td><td>0.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-3</td><td>Y</td><td>Reduced transcript levels (mild)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-3T>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5-2A>G</td><td>X</td><td>138633219</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.7</td><td>3.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS5-2A>G</td><td>X</td><td>138633219</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.5</td><td>8.1</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor-1A>G </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS6-1G>A</td><td>X</td><td>138642899</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.6</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>A </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS6-1G>C</td><td>X</td><td>138642899</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>C </td></tr>
<tr><td>Hemophilia B </td><td>1/25000</td><td>F9</td><td>X-linked recessive </td><td>  NM_000133:IVS7-1G>A</td><td>X</td><td>138643682</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.7</td><td>-2.9</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Reduced transcript levels (severe)</td><td>vonKodolitsch Hemophilia 12:258-69</td><td>acceptor0G>A </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS10-2A>T (IVS11?)</td><td>12</td><td>32949234</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.9</td><td>4.5</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>T </td></tr>
<tr><td>Arrhythmogenic right ventricular dysplasia</td><td>  1-5 / 10 000</td><td>PKP2</td><td>autosomal recessive or dominant</td><td>NM_004572:IVS10-1G>C  (IVS11?)</td><td>12</td><td>32949233</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.9</td><td>4.6</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>C </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYL3</td><td>inherited or sporadic</td><td>NM_000258:IVS4-2A>G</td><td>3</td><td>46899953</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.6</td><td>0.5</td><td>-8.2</td><td>rs111617556</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS25-3C>G</td><td>11</td><td>47356763</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.6</td><td>6.7</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-2C>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS19-2A>G</td><td>11</td><td>47361343</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.5</td><td>1.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-1A>G </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS21-1G>A</td><td>11</td><td>47360231</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.1</td><td>0.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>A </td></tr>
<tr><td>Hypertrophic cardiomyopathy</td><td>1/500<sup>8</sup></td><td>MYBPC3</td><td>inherited or sporadic</td><td>NM_000256:IVS9-1G>C</td><td>11</td><td>47368581</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.5</td><td>-4.8</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor0G>C </td></tr>
<tr><td>Dilated cardiomyopathy</td><td>2/10 000<sup>9</sup></td><td>DNAJC19</td><td>inherited or sporadic</td><td>NM_145261:IVS3-3C>G</td><td>3</td><td>180704813</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.6</td><td>5.6</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Fei J. J Clin Exp Cardiolog S. 2013;12:2</td><td>acceptor-2C>G </td></tr>
<tr><td>Classical homocystinuria </td><td>1-9 / 100 000</td><td>CBS</td><td>Autosomal recessive</td><td>  NM_000071:c.829-2A>T</td><td>21</td><td>44483190</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6</td><td>-1.4</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Kang D. The Korean Journal of Laboratory Medicine. 2010;30(5):516-520.</td><td>acceptor-1A>T </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2B6</td><td>autosomal recessive</td><td>NM_000767:15582C>G (c.485-18C>G)</td><td>19</td><td>41512792</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.1</td><td>8.8</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Wang J. Pharmacogenet Genomics. 2006;16(3):191-198.</td><td>acceptor-17C>G </td></tr>
<tr><td>Stargardt disease and AMD</td><td>-</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.2588G>C</td><td>1</td><td>94517254</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.6</td><td>9.7</td><td>-1.9</td><td>rs76157638</td><td>0.18</td><td>0.001</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>acceptor1G>C </td></tr>
<tr><td>Stargardt disease and AMD</td><td>-</td><td>ABCA4</td><td>AR and AD</td><td>NM_000350:c.2588G>C</td><td>1</td><td>94517254</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3.9</td><td>9.8</td><td>5.9</td><td>rs76157638</td><td>0.18</td><td>0.001</td><td>Exonic</td><td>3</td><td>N</td><td>-</td><td>Allikmets R. Gene. 1998;215(1):111-122</td><td>acceptor3G>C </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1187-1G>A</td><td>19</td><td>11223953</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.9</td><td>0.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor0G>A </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1187-1G>A</td><td>19</td><td>11223953</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.7</td><td>2.5</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor1G>A </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1988-2A>G</td><td>19</td><td>11231044</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.8</td><td>4.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor-1A>G </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1988-2A>G</td><td>19</td><td>11231044</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3.7</td><td>3.9</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor-1A>G </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1988-2A>T</td><td>19</td><td>11231044</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.8</td><td>5.3</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor-1A>T </td></tr>
<tr><td>Autosomal Dominant Hypercholesterolemia</td><td>1:3000/1:500</td><td>LDLR</td><td>autosomal dominant</td><td>NM_000527:c.1988-2A>T</td><td>19</td><td>11231044</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.9</td><td>5.7</td><td>2.8</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>3</td><td>N</td><td>-</td><td>Bertolini S. Atherosclerosis. 2013;227(2):342-348.</td><td>acceptor3A>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.4987-1G>A</td><td>17</td><td>41219713</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.8</td><td>-2.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor0G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.476-2A>G</td><td>13</td><td>32900377</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.1</td><td>6</td><td>-8.2</td><td>rs81002853</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor-1A>G </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.7008-2A>T</td><td>13</td><td>32928996</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.8</td><td>4.4</td><td>-7.4</td><td>rs81002823</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor-1A>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.7008-2A>T</td><td>13</td><td>32928996</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-1</td><td>1.6</td><td>2.6</td><td>rs81002823</td><td>-</td><td>-</td><td>Exonic</td><td>3</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor3A>T </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA2</td><td>N/A</td><td>NM_000059:c.8755-1G>A</td><td>13</td><td>32953453</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.3</td><td>-4.3</td><td>-7.6</td><td>rs81002812</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic (deletion)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor0G>A </td></tr>
<tr><td>Hereditary breast cancer</td><td>2500 new cases each year in Canada</td><td>BRCA1</td><td>N/A</td><td>NM_007294:c.213-11T>G</td><td>17</td><td>41256984</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.8</td><td>1.4</td><td>-2.4</td><td>rs80358061</td><td>-</td><td>-</td><td>Intronic</td><td>-10</td><td>Y</td><td>Cryptic (retention)</td><td>Colombo M. PLoS One. 2013;8(2):e57173</td><td>acceptor-10T>G </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD1</td><td>autosomal dominant</td><td>NM_001009944:IVS20-16C>G</td><td>16</td><td>2155491</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.4</td><td>6.3</td><td>-1.1</td><td>rs11640813</td><td>-</td><td>-</td><td>Intronic</td><td>-15</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>acceptor-15C>G </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD1</td><td>autosomal dominant</td><td>NM_001009944:IVS37-10C>A</td><td>16</td><td>2143104</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>4.9</td><td>2.9</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-9</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>acceptor-9C>A </td></tr>
<tr><td>Autosomal Dominant Polycystic Kidney Disease</td><td>1/600-1/1000</td><td>PKD2</td><td>autosomal dominant</td><td>NM_000297:IVS7-1G>A</td><td>4</td><td>88977237</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.3</td><td>-1.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Garcia-Gonzalez MA. Mol Genet Metab. 2007;92(1-2):160-167.</td><td>acceptor0G>A </td></tr>
<tr><td>Glycerol Kinase Deficiency</td><td>unknown - rare</td><td>GK</td><td>X-linked recessive</td><td>NM_203391:IVS9-1G>A</td><td>X</td><td>30725672</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.6</td><td>3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Hellerud C. Clinical chemistry and laboratory medicine. 2003;41(1):46-55</td><td>acceptor0G>A </td></tr>
<tr><td>Glycerol Kinase Deficiency</td><td>unknown - rare</td><td>GK</td><td>X-linked recessive</td><td>NM_203391:IVS10-1G>A</td><td>X</td><td>30718954</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.7</td><td>1.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Hellerud C. Mol Genet Metab. 2003;79(3):149-159.</td><td>acceptor0G>A </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.915-3C>G</td><td>7</td><td>286378</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.2</td><td>7.2</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>acceptor-2C>G </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.915-3C>G</td><td>7</td><td>286378</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-1.8</td><td>5.5</td><td>7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>acceptor-2C>G </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.1322-2A>G</td><td>7</td><td>296618</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>1.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>acceptor-1A>G </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.1404-1G>A</td><td>7</td><td>296970</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.9</td><td>5.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>acceptor0G>A </td></tr>
<tr><td>Raine Syndrome (neonatal osteosclerotic dysplasia)</td><td>14 reported cases</td><td>FAM20C</td><td>autosomal recessive</td><td>NM_020223:c.1404-1G>A</td><td>7</td><td>296970</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-1.5</td><td>6.7</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Simpson MA. Am J Hum Genet. 2007;81(5):906-912</td><td>acceptor1G>A </td></tr>
<tr><td>Dystrophic epidermolysis bullosa</td><td>1-9 / 100 000</td><td>COL7A1</td><td>autosomal recessive or dominant</td><td>NM_000094:IVS35-1G>C</td><td>3</td><td>48621809</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.8</td><td>4.5</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Wessagowit V. J Invest Dermatol. 2005;124(4):863-866.</td><td>acceptor0G>C </td></tr>
<tr><td>Isovaleric acidemia</td><td>1-9 / 100 000</td><td>IVD</td><td>Autosomal recessive</td><td>NM_002225:c.794-1G>A</td><td>15</td><td>40707087</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.4</td><td>-2.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (retention)</td><td>Vockley J. Am J Hum Genet. 2000;66(2):356-367.</td><td>acceptor0G>A </td></tr>
<tr><td>Isovaleric acidemia</td><td>1-9 / 100 000</td><td>IVD</td><td>Autosomal recessive</td><td>NM_002225:c.466-2A>G</td><td>15</td><td>40703457</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.9</td><td>-0.3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>No mRNA</td><td>Vockley J. Am J Hum Genet. 2000;66(2):356-367.</td><td>acceptor-1A>G </td></tr>
<tr><td>X-Linked hypophosphatemic rickets </td><td><1 / 1 000 000</td><td>PHEX</td><td>X-linked dominant</td><td>NM_000444:c.1174-1G>A </td><td>X</td><td>22132575</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8</td><td>0.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Song HR. J Korean Med Sci. 2007;22(6):981-986</td><td>acceptor0G>A </td></tr>
<tr><td>Ectodermal dysplasia-skin fragility syndrome</td><td>unknown</td><td>PKP1</td><td>autosomal recessive</td><td>NM_000299:IVS10-2A>G</td><td>1</td><td>201293554</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.8</td><td>4.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Wessagowit V. Acta Derm Venereol. 2005;85(5):386-388.</td><td>acceptor-1A>G </td></tr>
<tr><td>Ectodermal dysplasia-skin fragility syndrome</td><td>unknown</td><td>PKP1</td><td>autosomal recessive</td><td>NM_000299:IVS10-2A>G</td><td>1</td><td>201293554</td><td>Cryptic</td><td>ACCEPTOR</td><td>strengthen</td><td>7.5</td><td>7.9</td><td>0.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Wessagowit V. Acta Derm Venereol. 2005;85(5):386-388.</td><td>acceptor-1A>G </td></tr>
<tr><td>Ectodermal dysplasia-skin fragility syndrome</td><td>unknown</td><td>PKP1</td><td>autosomal recessive</td><td>NM_000299:IVS10-2A>G</td><td>1</td><td>201293554</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-2.2</td><td>5.4</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Wessagowit V. Acta Derm Venereol. 2005;85(5):386-388.</td><td>acceptor-1A>G </td></tr>
<tr><td>Ectodermal dysplasia-skin fragility syndrome</td><td>unknown</td><td>PKP1</td><td>autosomal recessive</td><td>NM_000299:IVS1-1G>A</td><td>1</td><td>201263069</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>16.4</td><td>8.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Leaky and cryptic</td><td>Wessagowit V. Acta Derm Venereol. 2005;85(5):386-388.</td><td>acceptor0G>A </td></tr>
<tr><td>Ectodermal dysplasia-skin fragility syndrome</td><td>unknown</td><td>PKP1</td><td>autosomal recessive</td><td>NM_000299:IVS1-1G>A</td><td>1</td><td>201263069</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.9</td><td>11.1</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Leaky and cryptic</td><td>Wessagowit V. Acta Derm Venereol. 2005;85(5):386-388.</td><td>acceptor1G>A </td></tr>
<tr><td>Alzheimer's Disease</td><td>50-250/1000</td><td>SORL1</td><td>N/A</td><td>NM_003105.5:c.3581-18C>G</td><td>11</td><td>121454149</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.5</td><td>9.2</td><td>-1.3</td><td>rs73595277</td><td>10.528</td><td>0.217</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Kölsch H. Brain Res. 2009;1264:1-6.</td><td>acceptor-17C>G </td></tr>
<tr><td>Wagner disease and erosive vitreoretinopathy </td><td><1 / 1 000 000</td><td>VCAN</td><td>autosomal dominant</td><td>  NM_004385:c.4004-5T>A</td><td>5</td><td>82832821</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>7.1</td><td>-2.8</td><td>rs80356556</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>Cryptic</td><td>Mukhopadhyay A. Invest Ophthalmol Vis Sci. 2006;47(8):3565-3572</td><td>acceptor-4T>A </td></tr>
<tr><td>Wagner disease and erosive vitreoretinopathy </td><td><1 / 1 000 000</td><td>VCAN</td><td>autosomal dominant</td><td>  NM_004385:c.4004-5T>A</td><td>5</td><td>82832821</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>7.1</td><td>-2.8</td><td>rs80356556</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>Cryptic</td><td>Mukhopadhyay A. Invest Ophthalmol Vis Sci. 2006;47(8):3565-3572</td><td>acceptor-4T>A </td></tr>
<tr><td>Wagner disease and erosive vitreoretinopathy </td><td><1 / 1 000 000</td><td>VCAN</td><td>autosomal dominant</td><td>  NM_004385:c.4004-5T>C</td><td>5</td><td>82832821</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>9.3</td><td>-0.6</td><td>rs80356556</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>N/A</td><td>Mukhopadhyay A. Invest Ophthalmol Vis Sci. 2006;47(8):3565-3572</td><td>acceptor-4T>C </td></tr>
<tr><td>Wagner disease and erosive vitreoretinopathy </td><td><1 / 1 000 000</td><td>VCAN</td><td>autosomal dominant</td><td>  NM_004385:c.4004-1G>A</td><td>5</td><td>82832825</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.9</td><td>2.3</td><td>-7.6</td><td>rs80356554</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mukhopadhyay A. Invest Ophthalmol Vis Sci. 2006;47(8):3565-3572</td><td>acceptor0G>A </td></tr>
<tr><td>Wagner disease and erosive vitreoretinopathy </td><td><1 / 1 000 000</td><td>VCAN</td><td>autosomal dominant</td><td>  NM_004385:c.4004-1G>A</td><td>5</td><td>82832825</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.9</td><td>2.3</td><td>-7.6</td><td>rs80356554</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mukhopadhyay A. Invest Ophthalmol Vis Sci. 2006;47(8):3565-3572</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL7A1</td><td>-</td><td>NM_000094:IVS30-1G>A</td><td>3</td><td>48623053</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>4.4</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Wessagowit V. J Dermatol Sci. 2005;40(2):73-84.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL7A1</td><td>-</td><td>NM_000094:IVS30-1G>A</td><td>3</td><td>48623053</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.5</td><td>8.7</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Cryptic</td><td>Wessagowit V. J Dermatol Sci. 2005;40(2):73-84.</td><td>acceptor1G>A </td></tr>
<tr><td>-</td><td>-</td><td>COL7A1</td><td>-</td><td>NM_000094:IVS2-3C>G </td><td>3</td><td>48631132</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.3</td><td>2.3</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Leaky cryptic (retention)</td><td>Wessagowit V. J Dermatol Sci. 2005;40(2):73-84.</td><td>acceptor-2C>G </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS2-3C>T</td><td>7</td><td>117149085</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.2</td><td>11.6</td><td>-1.7</td><td>rs200337193</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>-2</td><td>N</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-2C>T </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS3-1G>A</td><td>X</td><td>138623234</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.3</td><td>-2.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS7-1G>A</td><td>X</td><td>138643682</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.7</td><td>-2.9</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>FGFR2</td><td>-</td><td>NM_000141:IVS7-3T>G</td><td>10</td><td>123276980</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>9.7</td><td>-4.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-2T>G </td></tr>
<tr><td>-</td><td>-</td><td>FGFR2</td><td>-</td><td>NM_000141:c.940G>T</td><td>10</td><td>123276977</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>11.8</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor1G>T </td></tr>
<tr><td>-</td><td>-</td><td>LPL</td><td>-</td><td>NM_000237:IVS2-1G>A</td><td>8</td><td>19809279</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.7</td><td>0.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>RB (RB1)</td><td>-</td><td>NM_000321:IVS20-2A>G</td><td>13</td><td>49037865</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.4</td><td>-2.8</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>APOE</td><td>-</td><td>NM_000041:IVS3-2A>G</td><td>19</td><td>45411788</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.8</td><td>2.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492.3:c.274G>T</td><td>7</td><td>117170953</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.8</td><td>12.6</td><td>-2.2</td><td>rs121908751</td><td>-</td><td>-</td><td>Nonsense</td><td>1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor1G>T </td></tr>
<tr><td>-</td><td>-</td><td>DMD</td><td>-</td><td>NM_000109:IVS57-2A>C</td><td>X</td><td>31497222</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.9</td><td>4.6</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>C </td></tr>
<tr><td>-</td><td>-</td><td>DMD</td><td>-</td><td>NM_000109:IVS57-2A>C</td><td>X</td><td>31497222</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3</td><td>5.2</td><td>2.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>9</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor9A>C </td></tr>
<tr><td>-</td><td>-</td><td>F12</td><td>-</td><td>NM_000505:IVS13-1G>A</td><td>5</td><td>176829461</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.8</td><td>-1.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>F12</td><td>-</td><td>NM_000505:IVS13-1G>A</td><td>5</td><td>176829461</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.1</td><td>3.1</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor1G>A </td></tr>
<tr><td>-</td><td>-</td><td>GAA</td><td>-</td><td>NM_000152:IVS1-13T>G</td><td>17</td><td>78078341</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13</td><td>11.1</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-12T>G </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1-15T>G</td><td>11</td><td>5248044</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.4</td><td>7.7</td><td>-1.7</td><td>rs35456885</td><td>-</td><td>-</td><td>Intronic</td><td>-14</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-14T>G </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS1-15T>G</td><td>11</td><td>5248044</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3.7</td><td>5.1</td><td>8.7</td><td>rs35456885</td><td>-</td><td>-</td><td>Intronic</td><td>-14</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-14T>G </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:IVS2-2A>G</td><td>11</td><td>5246958</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.3</td><td>5.2</td><td>-8.2</td><td>rs33914668</td><td>0.08</td><td>0.001</td><td>Intronic</td><td>-1</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:IVS6-2A>G</td><td>X</td><td>148582570</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.6</td><td>4.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:IVS3-2A>G</td><td>X</td><td>148582570</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>8.9</td><td>16.5</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:IVS7-1G>C</td><td>X</td><td>148568630</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.4</td><td>-2.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:IVS7-8T>G</td><td>X</td><td>148568637</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.4</td><td>2.4</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-7</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-7T>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:IVS7-8T>G</td><td>X</td><td>148568637</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.6</td><td>11.3</td><td>8.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-7</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-7T>G </td></tr>
<tr><td>-</td><td>-</td><td>PAH</td><td>-</td><td>NM_000277:IVS11-11G>A</td><td>12</td><td>103237568</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.2</td><td>4.8</td><td>-0.4</td><td>rs5030855</td><td>0.12</td><td>0.003</td><td>Intronic</td><td>-10</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-10G>A </td></tr>
<tr><td>-</td><td>-</td><td>PAH</td><td>-</td><td>NM_000277:IVS11-11G>A</td><td>12</td><td>103237568</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.5</td><td>2.7</td><td>8.2</td><td>rs5030855</td><td>0.12</td><td>0.003</td><td>Intronic</td><td>-9</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-9G>A </td></tr>
<tr><td>-</td><td>-</td><td>ALDOB</td><td>-</td><td>NM_000035:IVS6-1G>A</td><td>9</td><td>104187910</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.6</td><td>2.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS22-1G>A</td><td>7</td><td>117282491</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.2</td><td>2.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS22-1G>A</td><td>7</td><td>117282491</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-4.9</td><td>3.3</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor1G>A </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS2-3C>T</td><td>7</td><td>117149085</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.2</td><td>11.6</td><td>-1.7</td><td>rs200337193</td><td>0.1</td><td>0.002</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-2C>T </td></tr>
<tr><td>-</td><td>-</td><td>CFTR</td><td>-</td><td>NM_000492:IVS2-3C>T</td><td>7</td><td>117149085</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>5.1</td><td>5.7</td><td>0.6</td><td>rs200337193</td><td>0.1</td><td>0.002</td><td>Exonic</td><td>2</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor2C>T </td></tr>
<tr><td>-</td><td>-</td><td>COL2A1</td><td>-</td><td>NM_001844:IVS20-2A>G</td><td>12</td><td>48380961</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.3</td><td>5.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>COL2A1</td><td>-</td><td>NM_001844:IVS20-2A>G</td><td>12</td><td>48380961</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>4.7</td><td>5.7</td><td>1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-2A>G </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS4-2A>G</td><td>X</td><td>138630520</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3</td><td>4.5</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.2</td><td>3.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>F9</td><td>-</td><td>NM_000133:IVS4-1G>C</td><td>X</td><td>138630521</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.2</td><td>6.2</td><td>6</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>2</td><td>N</td><td>No residual natural splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor2G>C </td></tr>
<tr><td>-</td><td>-</td><td>FGFR2</td><td>-</td><td>NM_000141:IVS7-2A>G</td><td>10</td><td>123276979</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>5.8</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>FGFR2</td><td>-</td><td>NM_000141:IVS7-2A>G</td><td>10</td><td>123276979</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.5</td><td>8</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>-</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>CYP21 (CYP21A2)</td><td>-</td><td>NM_001128590:IVS2-13C>A (g.31974574C>A)</td><td>6</td><td>32006858</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.7</td><td>7.6</td><td>-2.1</td><td>rs6467</td><td>69.42</td><td>0.446</td><td>Intronic</td><td>-12</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-12C>A </td></tr>
<tr><td>-</td><td>-</td><td>CYP21 (CYP21A2)</td><td>-</td><td>NM_001128590:IVS2-13C>G (g.31974574C>G)</td><td>6</td><td>32006858</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>10.5</td><td>-1.6</td><td>rs6467</td><td>0.03</td><td>0.446</td><td>Intronic</td><td>-12</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-12C>G </td></tr>
<tr><td>-</td><td>-</td><td>CYP21 (CYP21A2)</td><td>-</td><td>NM_001128590:IVS2-13C>G (g.31974574C>G)</td><td>6</td><td>32006858</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.7</td><td>8.2</td><td>-1.6</td><td>rs6467</td><td>0.03</td><td>0.446</td><td>Intronic</td><td>-12</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-12C>G </td></tr>
<tr><td>-</td><td>-</td><td>CYP21 (CYP21A2)</td><td>-</td><td>NM_001128590:g.32006858C>G</td><td>6</td><td>32006858</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.7</td><td>8</td><td>7.3</td><td>rs6467</td><td>0.03</td><td>0.446</td><td>Intronic</td><td>-12</td><td>Y</td><td>Residual splicing</td><td>Rogan PK. Hum Mutat. 1998;12(3):153-171.</td><td>acceptor-12C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5 / 10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:IVS10-2A>G</td><td>17</td><td>41243051</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.8</td><td>0.6</td><td>-8.2</td><td>rs80358019</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Svojanovsky SR.  Hum Mutat. 2000;16(3):264.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5 / 10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:IVS10-2A>G</td><td>17</td><td>41243051</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.6</td><td>10.2</td><td>7.6</td><td>rs80358019</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Svojanovsky SR.  Hum Mutat. 2000;16(3):264.</td><td>acceptor-1A>G </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LIPA</td><td>Autosomal Recessive</td><td>NM_000235:IVS6-2A>G</td><td>10</td><td>90983589</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.3</td><td>5.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor-1A>G </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:IVS6-3C>A</td><td>8</td><td>19816768</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.7</td><td>2.5</td><td>-4.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor-2C>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:IVS2-1G>A</td><td>8</td><td>19809279</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.7</td><td>0.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor0G>A </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:IVS6-3C>T</td><td>8</td><td>19816768</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.7</td><td>5.1</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor-2C>T </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>APOE</td><td>Autosomal Recessive</td><td>NM_000041:IVS3-2A>G</td><td>19</td><td>45411788</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.8</td><td>2.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor-1A>G </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LDLR</td><td>Autosomal Recessive</td><td>NM_000527:g.11222190A>T</td><td>19</td><td>11222190</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>16.1</td><td>14.8</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor1A>T </td></tr>
<tr><td>Atherosclerosis</td><td><1 / 1 000 000</td><td>LPL</td><td>Autosomal Recessive</td><td>NM_000237:g.19810821G>A</td><td>8</td><td>19810821</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.5</td><td>12.6</td><td>-1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>von Kodolitsch Y. Circulation. 1999;100(7):693-699.</td><td>acceptor1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-12C>G (IVS2)</td><td>17</td><td>41267808</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>6.1</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-11</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-11C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-13C>A (IVS2)</td><td>17</td><td>41267809</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>5.7</td><td>-2.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-12C>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-13C>G (IVS2)</td><td>17</td><td>41267809</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>6.2</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-12C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-1G>A (IVS2)</td><td>17</td><td>41267797</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.8</td><td>0.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-9C>G (IVS2)</td><td>17</td><td>41267805</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>6.2</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-8</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-8C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-18T>G (IVS4)</td><td>17</td><td>41258568</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>8.7</td><td>-1.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-17T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-1G>T (IVS4)</td><td>17</td><td>41258551</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>1.5</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-20T>G (IVS4)</td><td>17</td><td>41258570</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>9.2</td><td>-1.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-19</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-19T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-2A>G (IVS4)</td><td>17</td><td>41258552</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.3</td><td>2.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135A>T (p.K45N)</td><td>17</td><td>41258550</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>9</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.213-11T>G (IVS5)</td><td>17</td><td>41256984</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.8</td><td>1.4</td><td>-2.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-10</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-10T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.213-1G>A (IVS5)</td><td>17</td><td>41256974</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.8</td><td>-3.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.213-3C>G (IVS5)</td><td>17</td><td>41256976</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.8</td><td>-2.2</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-1G>A (IVS6)</td><td>17</td><td>41256279</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12</td><td>4.4</td><td>-7.6</td><td>rs80358116</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-1G>T (IVS6)</td><td>17</td><td>41256279</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>3.2</td><td>-8.7</td><td>rs80358116</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-2A>C (IVS6)</td><td>17</td><td>41256280</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12</td><td>4.6</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-2A>T (IVS6)</td><td>17</td><td>41256280</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>4.6</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-3C>G (IVS6)</td><td>17</td><td>41256281</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>6</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.442-2A>C (IVS7)</td><td>17</td><td>41251899</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.2</td><td>-4.2</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.594-2A>C (IVS9)</td><td>17</td><td>41247941</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.2</td><td>2.7</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.671-15T>A (IVS10)</td><td>17</td><td>41246892</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.5</td><td>7.6</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-14</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-14T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.671-1G>T (IVS10)</td><td>17</td><td>41246878</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.5</td><td>0.8</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.671-2A>C (IVS10)</td><td>17</td><td>41246879</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.5</td><td>2.1</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4097-2A>G (IVS11)</td><td>17</td><td>41243051</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.8</td><td>0.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4097-1G>A (IVS11)</td><td>17</td><td>41243050</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.8</td><td>1.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4485-18T>A (IVS14)</td><td>17</td><td>41226556</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.9</td><td>12.5</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-17T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4485-2A>G (IVS14)</td><td>17</td><td>41226540</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.9</td><td>5.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4485-1G>A (IVS14)</td><td>17</td><td>41226539</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.9</td><td>6.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4485-1G>A (IVS14)</td><td>17</td><td>41226539</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.9</td><td>6.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-10T>A (IVS15)</td><td>17</td><td>41223265</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.1</td><td>9.5</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-9</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-9T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-16C>G (IVS15)</td><td>17</td><td>41223271</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.1</td><td>11</td><td>-1.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-15</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-15C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-1G>A (IVS15)</td><td>17</td><td>41223256</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.1</td><td>4.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-2A>G (IVS15)</td><td>17</td><td>41223257</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.1</td><td>3.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-8C>G (IVS15)</td><td>17</td><td>41223263</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.1</td><td>10.1</td><td>-1.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-7</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-7C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4987-1G>A (IVS16)</td><td>17</td><td>41219713</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.8</td><td>-2.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4987A>T (p.M1663L)</td><td>17</td><td>41219712</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>4.8</td><td>3.5</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5075-1G>A (IVS17)</td><td>17</td><td>41215969</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.3</td><td>4.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5075-1G>C (IVS17)</td><td>17</td><td>41215969</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.3</td><td>5</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5075-2A>T (IVS17)</td><td>17</td><td>41215970</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.3</td><td>4.8</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153-1G>A (IVS18)</td><td>17</td><td>41215391</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>1.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153-1G>A (IVS18)</td><td>17</td><td>41215391</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>1.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153-6C>A (IVS18)</td><td>17</td><td>41215396</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.2</td><td>6.8</td><td>-2.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-5C>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153G>C (p.W1718S)</td><td>17</td><td>41215390</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.2</td><td>7.3</td><td>-1.9</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5194-1G>A (IVS19)</td><td>17</td><td>41209153</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.6</td><td>-1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5194-2A>G (IVS19)</td><td>17</td><td>41209154</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.6</td><td>-1.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5278-14C>G (IVS20)</td><td>17</td><td>41203148</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>17.9</td><td>16.6</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-13</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-13C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5278-1G>A (IVS20)</td><td>17</td><td>41203135</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>17.9</td><td>10.3</td><td>-7.6</td><td>rs80358099</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5278-1G>T (IVS20)</td><td>17</td><td>41203135</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>17.9</td><td>9.1</td><td>-8.7</td><td>rs80358099</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5333-1G>C (IVS21)</td><td>17</td><td>41201212</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.3</td><td>-3</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-1G>A (IVS22)</td><td>17</td><td>41199721</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>-0.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-1G>C (IVS22)</td><td>17</td><td>41199721</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>0.1</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-2A>G (IVS22)</td><td>17</td><td>41199722</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>-0.8</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-2A>T (IVS22)</td><td>17</td><td>41199722</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>-0.1</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5468-10C>A (IVS23)</td><td>17</td><td>41197829</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.4</td><td>9.4</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-9</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-9C>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5468-18T>A (IVS23)</td><td>17</td><td>41197837</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.4</td><td>10</td><td>-1.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-17T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5468-1G>A (IVS23)</td><td>17</td><td>41197820</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.4</td><td>3.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-13C>A (IVS2)</td><td>17</td><td>41267809</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>5.7</td><td>-2.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-12C>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.81-9C>G (IVS2)</td><td>17</td><td>41267805</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.8</td><td>6.2</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-8</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-8C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-2A>G (IVS4)</td><td>17</td><td>41258552</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>2.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.68-7T>A (IVS2)</td><td>13</td><td>32893207</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5</td><td>2.8</td><td>-2.1</td><td>rs81002830</td><td>0.236</td><td>-</td><td>Intronic</td><td>-6</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-6T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-3C>G (IVS6)</td><td>17</td><td>41256281</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>6</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.671-2A>C (IVS10)</td><td>17</td><td>41246879</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.5</td><td>2.1</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.476-2A>G (IVS5)</td><td>13</td><td>32900377</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>14.1</td><td>6</td><td>-8.2</td><td>rs81002853</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.517-2A>G (IVS6)</td><td>13</td><td>32900634</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>14.5</td><td>6.3</td><td>-8.2</td><td>rs81002858</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.517-1G>A (IVS6)</td><td>13</td><td>32900635</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.5</td><td>6.9</td><td>-7.6</td><td>rs81002849</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.632-1G>C (IVS7)</td><td>13</td><td>32903579</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.1</td><td>-0.2</td><td>-7.3</td><td>rs81002820</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.682-1G>C (IVS8)</td><td>13</td><td>32905055</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.9</td><td>-2.4</td><td>-7.3</td><td>rs81002831</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6842-11T>A (IVS11)</td><td>13</td><td>32918684</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.9</td><td>3.1</td><td>-2.8</td><td>rs81002877</td><td>-</td><td>-</td><td>Intronic</td><td>-10</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-10T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6842G>T (p.G2281V)</td><td>13</td><td>32918695</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.9</td><td>3.7</td><td>-2.2</td><td>rs80358908</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6938-2A>G (IVS12)</td><td>13</td><td>32920962</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.3</td><td>-5.9</td><td>-8.2</td><td>rs81002863</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4097-2A>G (IVS11)</td><td>17</td><td>41243051</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.8</td><td>0.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4097-1G>A (IVS11)</td><td>17</td><td>41243050</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.8</td><td>1.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7008-2A>G (IVS13)</td><td>13</td><td>32928996</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.8</td><td>3.6</td><td>-8.2</td><td>rs81002823</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4485-2A>G (IVS14)</td><td>17</td><td>41226540</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.9</td><td>5.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7008-2A>T (IVS13)</td><td>13</td><td>32928996</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.8</td><td>4.4</td><td>-7.4</td><td>rs81002823</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7436-14T>G (IVS14)</td><td>13</td><td>32930551</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.4</td><td>4.7</td><td>-1.7</td><td>rs81002814</td><td>-</td><td>-</td><td>Intronic</td><td>-13</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-13T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7436-17T>G (IVS14)</td><td>13</td><td>32930548</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.4</td><td>5</td><td>-1.4</td><td>rs81002829</td><td>-</td><td>-</td><td>Intronic</td><td>-16</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-16T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.4676-1G>A (IVS15)</td><td>17</td><td>41223256</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.1</td><td>4.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7618-16T>G (IVS15)</td><td>13</td><td>32931863</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.9</td><td>5.6</td><td>-1.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-15</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-15T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7618-1G>A (IVS15)</td><td>13</td><td>32931878</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.9</td><td>-0.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7806-2A>G (IVS16)</td><td>13</td><td>32936658</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.8</td><td>2.6</td><td>-8.2</td><td>rs81002836</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7806-1G>T (IVS16)</td><td>13</td><td>32936659</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.8</td><td>2</td><td>-8.7</td><td>rs81002860</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5278-1G>T (IVS20)</td><td>17</td><td>41203135</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>17.9</td><td>9.1</td><td>-8.7</td><td>rs80358099</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5278-1G>T (IVS20)</td><td>17</td><td>41203135</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>11.9</td><td>13.8</td><td>1.9</td><td>rs80358099</td><td>-</td><td>-</td><td>Exonic</td><td>8</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor8G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-1G>T (IVS17)</td><td>13</td><td>32937315</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>2.5</td><td>-8.7</td><td>rs81002874</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-1G>C (IVS17)</td><td>13</td><td>32937315</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.3</td><td>4</td><td>-7.3</td><td>rs81002874</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8633-16C>G (IVS20)</td><td>13</td><td>32950791</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.1</td><td>9</td><td>-1.1</td><td>rs81002818</td><td>-</td><td>-</td><td>Intronic</td><td>-15</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-15C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8633-2A>G (IVS20)</td><td>13</td><td>32950805</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>1.9</td><td>-8.2</td><td>rs81002886</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8954-3C>G (IVS22)</td><td>13</td><td>32953884</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>4.1</td><td>-6</td><td>rs81002844</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9118-2A>G (IVS23)</td><td>13</td><td>32954142</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.9</td><td>5.7</td><td>-8.2</td><td>rs81002862</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9257-1G>C (IVS24)</td><td>13</td><td>32968825</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>16.4</td><td>9.1</td><td>-7.3</td><td>rs81002889</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9502-12T>G (IVS25)</td><td>13</td><td>32971023</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.6</td><td>6.4</td><td>-2.3</td><td>rs81002803</td><td>-</td><td>-</td><td>Intronic</td><td>-11</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-11T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9502-2A>C (IVS25)</td><td>13</td><td>32971033</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.6</td><td>1.2</td><td>-7.4</td><td>rs81002868</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9649-2A>G (IVS26)</td><td>13</td><td>32972297</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.4</td><td>2.2</td><td>-8.2</td><td>rs81002895</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7806-1G>T (IVS16)</td><td>13</td><td>32936659</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.8</td><td>2</td><td>-8.7</td><td>rs81002860</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7806-1G>T (IVS16)</td><td>13</td><td>32936659</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.4</td><td>3.8</td><td>1.4</td><td>rs81002860</td><td>-</td><td>-</td><td>Exonic</td><td>20</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor20G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-1G>T (IVS17)</td><td>13</td><td>32937315</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>2.5</td><td>-8.7</td><td>rs81002874</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-1G>C (IVS17)</td><td>13</td><td>32937315</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.3</td><td>4</td><td>-7.3</td><td>rs81002874</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8633-2A>G (IVS20)</td><td>13</td><td>32950805</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>1.9</td><td>-8.2</td><td>rs81002886</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8954-3C>G (IVS22)</td><td>13</td><td>32953884</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>4.1</td><td>-6</td><td>rs81002844</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9502-2A>C (IVS25)</td><td>13</td><td>32971033</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.6</td><td>1.2</td><td>-7.4</td><td>rs81002868</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-7C>G (IVS17)</td><td>13</td><td>32937309</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>9.2</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-6</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-6C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7977-7C>G (IVS17)</td><td>13</td><td>32937309</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>1.8</td><td>9.1</td><td>7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-6</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-6C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8633-2A>G (IVS20)</td><td>13</td><td>32950805</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>1.9</td><td>-8.2</td><td>rs81002886</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-6T>G (IVS3)</td><td>17</td><td>41258556</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>7.4</td><td>-2.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-5T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.518G>T (p.G173V)</td><td>13</td><td>32900637</td><td>Natural</td><td>ACCEPTOR</td><td>Strengthened</td><td>14.5</td><td>15</td><td>0.5</td><td>rs28897702</td><td>0.602</td><td>0.012</td><td>Missense</td><td>2</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor2G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.68-7T>A (IVS2)</td><td>13</td><td>32893207</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5</td><td>2.8</td><td>-2.1</td><td>rs81002830</td><td>0.24</td><td>-</td><td>Intronic</td><td>-6</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-6T>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.135-2A>G (IVS4)</td><td>17</td><td>41258552</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>2.1</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-1G>A (IVS6)</td><td>17</td><td>41256279</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12</td><td>4.4</td><td>-7.6</td><td>rs80358116</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-3C>T (IVS6)</td><td>17</td><td>41256281</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>10.3</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.302-3C>G (IVS6)</td><td>17</td><td>41256281</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>2.3</td><td>9.6</td><td>7.3</td><td>rs80358051</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic (retention)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-2C>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153-1G>A (IVS18)</td><td>17</td><td>41215391</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>1.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5153-1G>A (IVS18)</td><td>17</td><td>41215391</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-8.5</td><td>6.2</td><td>14.7</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.9118-2A>G (IVS23)</td><td>13</td><td>32954142</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.9</td><td>5.7</td><td>-8.2</td><td>rs81002862</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic (deletion)</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-1A>G </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2D6</td><td>-</td><td>NM_000106:IVS3-1G>A</td><td>22</td><td>42524947</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.1</td><td>3.5</td><td>-7.6</td><td>rs3892097 </td><td>10.117</td><td>0.19</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Rogan, P. K. Pharmacogenetics 13, 207–218 (2003)."</td><td>acceptor0G>A </td></tr>
<tr><td>Drug metabolism</td><td>N/A</td><td>CYP2D6</td><td>-</td><td>NM_000106:IVS1-1G>C</td><td>22</td><td>42525912</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.2</td><td>0.9</td><td>-7.3</td><td>rs201377835 </td><td>0.23</td><td>0.005</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Rogan, P. K. Pharmacogenetics 13, 207–218 (2003)."</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>CFLAR</td><td>-</td><td>NM_001127184:g.202006096G>A</td><td>2</td><td>202006096</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>17.4</td><td>9.9</td><td>-7.6</td><td>rs10190751 </td><td>23.6</td><td>0.339</td><td>Intronic</td><td>0</td><td>Y</td><td>Decreased skipping</td><td>"Rogan, Peter, and Eliseos Mucaki. arXiv preprint arXiv:1107.0716 (2011). "</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>ZNF713</td><td>-</td><td>NM_182633:g.55973939C>G  </td><td>7</td><td>55973939</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.9</td><td>10.8</td><td>-2</td><td>rs924900</td><td>9.2</td><td>0.171</td><td>Intronic</td><td>-6</td><td>Y</td><td>Increased skipping</td><td>"Rogan, Peter, and Eliseos Mucaki. arXiv preprint arXiv:1107.0716 (2011). "</td><td>acceptor-6C>G </td></tr>
<tr><td>-</td><td>-</td><td>USF1</td><td>-</td><td>NM_007122:g.161013165C>A</td><td>1</td><td>161013165</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.9</td><td>4.3</td><td>-1.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-14</td><td>N</td><td>-</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-14C>A </td></tr>
<tr><td>-</td><td>-</td><td>NME7</td><td>-</td><td>NM_013330:g.169272451T>A</td><td>1</td><td>169272451</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.1</td><td>8.7</td><td>-1.4</td><td>rs10800427</td><td>2.8</td><td>0.04</td><td>Intronic</td><td>-17</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-17T>A </td></tr>
<tr><td>-</td><td>-</td><td>DNAJC6</td><td>-</td><td>NM_014787:g.65830299T>G</td><td>1</td><td>65830299</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>16.1</td><td>15.2</td><td>-0.9</td><td>rs2296479</td><td>-</td><td>-</td><td>Intronic</td><td>-18</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-18T>G </td></tr>
<tr><td>-</td><td>-</td><td>RP11-211N11.5.1 (CASP7)</td><td>-</td><td>NM_033340:g.115470783T>G</td><td>10</td><td>115470783</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.6</td><td>9</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-14</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-14T>G </td></tr>
<tr><td>-</td><td>-</td><td>APIP</td><td>-</td><td>NM_015957:g.34905054C>G</td><td>11</td><td>34905054</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.6</td><td>4.7</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-2C>G </td></tr>
<tr><td>-</td><td>-</td><td>SCAF11 (SFRS2IP)</td><td>-</td><td>NM_004719:g.46355654T>G</td><td>12</td><td>46355654</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.2</td><td>7.5</td><td>-1.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-13</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-13T>G </td></tr>
<tr><td>-</td><td>-</td><td>SMARCD1</td><td>-</td><td>NM_139071:g.50480538G>C</td><td>12</td><td>50480538</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.5</td><td>1.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>ARHGEF7</td><td>-</td><td>NM_145735:g.111932609T>G</td><td>13</td><td>111932609</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.4</td><td>0.2</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-9</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-9T>G </td></tr>
<tr><td>-</td><td>-</td><td>SYNE2</td><td>-</td><td>NM_015180:g.64669514T>A</td><td>14</td><td>64669514</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>0</td><td>-2.8</td><td>rs189611387</td><td>0.227</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-4T>A </td></tr>
<tr><td>-</td><td>-</td><td>PIAS1</td><td>-</td><td>NM_016166:g.68445912T>A</td><td>15</td><td>68445912</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>16.9</td><td>15.4</td><td>-1.6</td><td>rs11633620</td><td>0.436</td><td>-</td><td>Intronic</td><td>-15</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-15T>A </td></tr>
<tr><td>-</td><td>-</td><td>RP11-403P17.5.1 (TK2)</td><td>-</td><td>NM_004614:g.66547767A>G</td><td>16</td><td>66547767</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6</td><td>-2.2</td><td>-8.2</td><td>rs2241619</td><td>15.124</td><td>0.257</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>WWOX</td><td>-</td><td>NM_016373:g.78312497C>A</td><td>16</td><td>78312497</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11</td><td>6.8</td><td>-4.2</td><td>rs8050128</td><td>47.741</td><td>0.499</td><td>Intronic</td><td>-2</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-2C>A </td></tr>
<tr><td>-</td><td>-</td><td>CENPN</td><td>-</td><td>NM_001100625:g.81060105T>G</td><td>16</td><td>81060105</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.6</td><td>4.7</td><td>-0.9</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-25</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-25T>G </td></tr>
<tr><td>-</td><td>-</td><td>SAP30BP</td><td>-</td><td>NM_013260:g.73698557C>T</td><td>17</td><td>73698557</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.2</td><td>13.5</td><td>-1.7</td><td>rs820232</td><td>98.792</td><td>0.039</td><td>Intronic</td><td>-2</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-2C>T </td></tr>
<tr><td>-</td><td>-</td><td>ZRANB3</td><td>-</td><td>NM_032143:g.136148401T>A</td><td>2</td><td>136148401</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>20.4</td><td>17.6</td><td>-2.8</td><td>rs75842485</td><td>13.348</td><td>-</td><td>Intronic</td><td>-10</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-10T>A </td></tr>
<tr><td>-</td><td>-</td><td>TTC27</td><td>-</td><td>NM_017735:g.32961745T>A</td><td>2</td><td>32961745</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8</td><td>6.5</td><td>-1.6</td><td>rs10200333</td><td>0.598</td><td>-</td><td>Intronic</td><td>-15</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-15T>A </td></tr>
<tr><td>-</td><td>-</td><td>APOL1</td><td>-</td><td>NM_145343:g.36657628T>G</td><td>22</td><td>36657628</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.1</td><td>9.3</td><td>-1.7</td><td>rs41368549</td><td>-</td><td>-</td><td>Intronic</td><td>-13</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-13T>G </td></tr>
<tr><td>-</td><td>-</td><td>TIMMDC1</td><td>-</td><td>NM_016589:g.119222366T>A</td><td>3</td><td>119222366</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.3</td><td>2.8</td><td>-2.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-12T>A </td></tr>
<tr><td>-</td><td>-</td><td>CTNNB1</td><td>-</td><td>NM_001904:g.41277214G>A</td><td>3</td><td>41277214</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.5</td><td>2.9</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>ARSB</td><td>-</td><td>NM_000046:g.78076488T>A</td><td>5</td><td>78076488</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.2</td><td>7.7</td><td>-2.6</td><td>rs183651028</td><td>0.092</td><td>0.002</td><td>Intronic</td><td>-2</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-2T>A </td></tr>
<tr><td>-</td><td>-</td><td>MDC1</td><td>-</td><td>NM_014641:g.30679289C>G</td><td>6</td><td>30679289</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.4</td><td>7.5</td><td>-1.9</td><td>rs147822906</td><td>1.509</td><td>0.028</td><td>Intronic</td><td>-7</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-7C>G </td></tr>
<tr><td>-</td><td>-</td><td>STYXL1</td><td>-</td><td>AK308912:g.75628461T>A</td><td>7</td><td>75628461</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>-14.6</td><td>-17.2</td><td>-2.6</td><td>rs4728538</td><td>12.009</td><td>0.212</td><td>Intronic</td><td>-9</td><td>Y</td><td>Alternate Exon</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-9T>A </td></tr>
<tr><td>-</td><td>-</td><td>TRRAP</td><td>-</td><td>NM_003496:g.98533187T>G</td><td>7</td><td>98533187</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.5</td><td>7.8</td><td>-1.7</td><td>rs62472016</td><td>3.656</td><td>0.059</td><td>Intronic</td><td>-14</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-14T>G </td></tr>
<tr><td>-</td><td>-</td><td>TRRAP</td><td>-</td><td>NM_003496:g.98591160G>C</td><td>7</td><td>98591160</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.7</td><td>-0.6</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>ARRDC1</td><td>-</td><td>NM_152285:g.140507906C>G</td><td>9</td><td>140507906</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>15.4</td><td>12.8</td><td>-2.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>Y</td><td>Low fidelity splicing</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-5C>G </td></tr>
<tr><td>-</td><td>-</td><td>FAM70A</td><td>-</td><td>NM_017938:g.119402264T>G</td><td>X</td><td>119402264</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>10.9</td><td>-1.1</td><td>rs41300936</td><td>-</td><td>-</td><td>Intronic</td><td>-21</td><td>Y</td><td>N/A</td><td>Shirley BC. Genomics Proteomics Bioinformatics. 2013;11(2):77-85.</td><td>acceptor-21T>G </td></tr>
<tr><td>-</td><td>-</td><td>SPG4 (SPAST)</td><td>-</td><td>NM_014946:c.1005-1G>T</td><td>2</td><td>32341187</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.6</td><td>-5.2</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>CHM</td><td>-</td><td>NM_000390:c.1380-6T>G</td><td>X</td><td>85155720</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.9</td><td>7</td><td>-2.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor-5T>G </td></tr>
<tr><td>-</td><td>-</td><td>CHM</td><td>-</td><td>NM_000390:c.1380-1G>A</td><td>X</td><td>85155715</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.9</td><td>2.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>NFI (NF1)</td><td>-</td><td>NM_000267:IVS39-12T>A</td><td>17</td><td>29663339</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.8</td><td>6.2</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-11</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor-11T>A </td></tr>
<tr><td>-</td><td>-</td><td>PHYH</td><td>-</td><td>NM_006214:IVS5-2A>G</td><td>10</td><td>13330543</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>1.6</td><td>-8.2</td><td>rs144169488</td><td>0.022</td><td>-</td><td>Intronic</td><td>-1</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>PHYH</td><td>-</td><td>NM_006214:IVS5-1G>T</td><td>10</td><td>13330542</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>1</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>XRCC4</td><td>-</td><td>NM_022406:g.82648943G>A</td><td>5</td><td>82648943</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>11.5</td><td>3.9</td><td>-7.6</td><td>rs1805377</td><td>32.09</td><td>0.478</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>IL19</td><td>-</td><td>NM_153758:g.207014348G>A</td><td>1</td><td>207014348</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>-0.3</td><td>-7.6</td><td>rs2243187</td><td>0.276</td><td>0.004</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>EXO1</td><td>-</td><td>NM_130398:g.242048615G>C</td><td>1</td><td>242048615</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>0</td><td>-7.3</td><td>rs4150000</td><td>0.206</td><td>0.003</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>LRRFIP2</td><td>-</td><td>NM_017724:g.37125298G>A</td><td>3</td><td>37125298</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.2</td><td>-4.4</td><td>-7.6</td><td>rs1419973</td><td>15.58</td><td>0.263</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>"Nalla, V. K. Hum. Mutat. 25, 334–342 (2005)."</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.5216-1G>A</td><td>17</td><td>41215391</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.2</td><td>1.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007300:c.213-2A>G</td><td>17</td><td>41256975</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.8</td><td>-4.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA2</td><td>-</td><td>NM_000059:c.8633-2A>G</td><td>13</td><td>32950805</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.1</td><td>1.9</td><td>-8.2</td><td>rs81002886</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA2</td><td>-</td><td>NM_000059:c.7977-7C>G</td><td>13</td><td>32937309</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>9.2</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-6</td><td>Y</td><td>Skipping and Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-6C>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA2</td><td>-</td><td>NM_000059:c.9118-2A>G</td><td>13</td><td>32954142</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>13.9</td><td>5.7</td><td>-8.2</td><td>rs81002862</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>FAH</td><td>-</td><td>NM_000137:c.554-1G>T </td><td>15</td><td>460605</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.7</td><td>1.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>FAH</td><td>-</td><td>NM_000137:c.554-1G>T </td><td>15</td><td>460605</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>0.7</td><td>3.5</td><td>2.8</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>5</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor5G>T </td></tr>
<tr><td>-</td><td>-</td><td>FAH</td><td>-</td><td>NM_000137:c.707-1G>T</td><td>15</td><td>465355</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.7</td><td>1.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>T </td></tr>
<tr><td>-</td><td>-</td><td>F12</td><td>-</td><td>NM_000505:c.1681-1G>A </td><td>5</td><td>176829461</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>5.8</td><td>-1.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>F12</td><td>-</td><td>NM_000505:c.1681-1G>A </td><td>5</td><td>176829461</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-5.1</td><td>3.1</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor1G>A </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.93-2A>G</td><td>11</td><td>5248031</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.4</td><td>1.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.93-2A>G</td><td>11</td><td>5248031</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-4</td><td>3.6</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>HBB</td><td>-</td><td>NM_000518:c.316-2A>G </td><td>11</td><td>5246958</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>13.3</td><td>5.2</td><td>-8.2</td><td>rs33914668</td><td>0.27</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:c.1007-1G>C </td><td>X</td><td>148568630</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.3</td><td>-2.9</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:c.880-2A>G</td><td>X</td><td>148571973</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.6</td><td>4.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:c.419-2A>G </td><td>X</td><td>148582570</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.7</td><td>4.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>IDS</td><td>-</td><td>NM_000202:c.419-2A>G </td><td>X</td><td>148582570</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>8.9</td><td>16.5</td><td>7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>MYBPC3b</td><td>-</td><td>NM_000256:g.47361343A>G</td><td>11</td><td>47361343</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.5</td><td>1.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>PMM2</td><td>-</td><td>NM_000303:c.448-1G>C</td><td>8</td><td>905494</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12.5</td><td>5.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>PMM2</td><td>-</td><td>NM_000303:c.448-1G>C</td><td>8</td><td>905494</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>5.2</td><td>7.7</td><td>2.5</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>4</td><td>Y</td><td>Skipping</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor4G>C </td></tr>
<tr><td>-</td><td>-</td><td>NSUN2</td><td>-</td><td>NM_017755:c.538-1G>C</td><td>5</td><td>6622214</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>6.5</td><td>-0.8</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor0G>C </td></tr>
<tr><td>-</td><td>-</td><td>NSUN2</td><td>-</td><td>NM_017755:c.538-1G>C</td><td>5</td><td>6622214</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3.5</td><td>5.4</td><td>1.9</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>7</td><td>Y</td><td>Cryptic</td><td>Mucaki EJ. Hum Mutat. 2013;34(4):557-565.</td><td>acceptor7G>C </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.135-6T>G (IVS3)</td><td>17</td><td>41258556</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>7.4</td><td>-2.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-5</td><td>Y</td><td>Skipping</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>acceptor-5T>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.135-2A>G (IVS4)</td><td>17</td><td>41258552</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.3</td><td>2.1</td><td>-8.2</td><td>rs80358065</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Cryptic</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>acceptor-1A>G </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.302-1G>A (IVS6)</td><td>17</td><td>41256279</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>12</td><td>4.4</td><td>-7.6</td><td>rs80358116</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Cryptic</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>acceptor0G>A </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.302-3C>T (IVS6)</td><td>17</td><td>41256281</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12</td><td>10.3</td><td>-1.7</td><td>rs80358065</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>acceptor-2C>T </td></tr>
<tr><td>-</td><td>-</td><td>BRCA1</td><td>-</td><td>NM_007294:c.302-3C>G (IVS6)</td><td>17</td><td>41256281</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>2.3</td><td>9.6</td><td>7.3</td><td>rs80358051</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic</td><td>"Tahsin, Mucaki and Rogan, 2011"</td><td>acceptor-2C>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1-1G>C</td><td>X</td><td>133607388</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>9.7</td><td>2.4</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1-1G>A</td><td>X</td><td>133607388</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>2.1</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1-1G>T</td><td>X</td><td>133607388</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>0.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1-2A>G</td><td>X</td><td>133607387</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>1.5</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS1-2A>T</td><td>X</td><td>133607387</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>9.7</td><td>2.3</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS2-1G>C</td><td>X</td><td>133609210</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>4</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS2-1G>A</td><td>X</td><td>133609210</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>3.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS2-1G>T</td><td>X</td><td>133609210</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>2.5</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3-1G>C</td><td>X</td><td>133620494</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>3</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3-1G>A</td><td>X</td><td>133620494</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>10.3</td><td>2.7</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3-1G>T</td><td>X</td><td>133620494</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.3</td><td>1.6</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS3-2A>G</td><td>X</td><td>133620493</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>10.3</td><td>2.2</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4-1G>C</td><td>X</td><td>133624217</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.7</td><td>7.4</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4-1G>T</td><td>X</td><td>133624217</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.7</td><td>6</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4-2A>G</td><td>X</td><td>133624216</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.7</td><td>6.6</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS4-2A>C</td><td>X</td><td>133624216</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.7</td><td>7.3</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5-1G>A</td><td>X</td><td>133627537</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.1</td><td>-0.5</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5-1G>A</td><td>X</td><td>133627537</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-3.3</td><td>4.9</td><td>8.2</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>Y</td><td>Skipping and cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5-1G>C</td><td>X</td><td>133627537</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.1</td><td>-0.2</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS5-1G>T</td><td>X</td><td>133627537</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.1</td><td>-1.6</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-1G>C</td><td>X</td><td>133632419</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>-2.7</td><td>-7.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-1G>A</td><td>X</td><td>133632419</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>-3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-1G>T</td><td>X</td><td>133632419</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>-4.2</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-2A>T</td><td>X</td><td>133632418</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>-2.8</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-3C>G</td><td>X</td><td>133632417</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>-1.4</td><td>-6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-2C>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS6-12T>A</td><td>X</td><td>133632408</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>4.6</td><td>2</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-11</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-11T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-1G>A</td><td>X</td><td>133632637</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>-4.8</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-1G>T</td><td>X</td><td>133632637</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>-5.9</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-2A>G</td><td>X</td><td>133632636</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>-5.4</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-2A>T</td><td>X</td><td>133632636</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>-4.6</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-3T>A</td><td>X</td><td>133632635</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>0.2</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-2T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-5T>G</td><td>X</td><td>133632633</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>-0.3</td><td>-3.1</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-4T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-5T>A</td><td>X</td><td>133632633</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>0</td><td>-2.8</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-4</td><td>Y</td><td>N/A</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-4T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-13T>A</td><td>X</td><td>133632625</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>2.8</td><td>0.3</td><td>-2.5</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-12T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-1G>A</td><td>X</td><td>133634059</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.9</td><td>1.3</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-1G>T</td><td>X</td><td>133634059</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.9</td><td>0.1</td><td>-8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>Y</td><td>Skipping and Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor0G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-2A>G</td><td>X</td><td>133634058</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.9</td><td>0.7</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-2A>T</td><td>X</td><td>133634057</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>8.9</td><td>1.4</td><td>-7.4</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-1A>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-3T>A</td><td>X</td><td>133634057</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.9</td><td>6.3</td><td>-2.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-2T>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-3T>G</td><td>X</td><td>133634057</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>8.9</td><td>4.5</td><td>-4.3</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-2T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS8-3T>G</td><td>X</td><td>133634056</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-1.3</td><td>7.4</td><td>8.7</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-2</td><td>Y</td><td>Cryptic</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-2T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133609211G>A</td><td>X</td><td>133609211</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>11.3</td><td>10.3</td><td>-1</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627538G>A</td><td>X</td><td>133627538</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.1</td><td>6.2</td><td>-1</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor1G>A </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627538G>T</td><td>X</td><td>133627538</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.1</td><td>4.9</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor1G>T </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:g.133627538G>C</td><td>X</td><td>133627538</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>7.1</td><td>5.2</td><td>-1.9</td><td>-</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor1G>C </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-10T>G</td><td>X</td><td>133632628</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>2.8</td><td>0.6</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-9</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-9T>G </td></tr>
<tr><td>Lesch-Nyhan disease</td><td>1-9 / 1 000 000</td><td>HPRT (HPRT1)</td><td>X-linked Recessive</td><td>NM_000194:IVS7-13T>G</td><td>X</td><td>133632625</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>2.8</td><td>0.8</td><td>-2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-12</td><td>Y</td><td>Skipping</td><td>O'Neill JP. Mutat Res. 1998;411(3):179-214.</td><td>acceptor-12T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>HMMR</td><td>Autosomal Dominant</td><td>NM_012484:g.162905690G>T</td><td>5</td><td>162905690</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>12.5</td><td>10.3</td><td>-2.2</td><td>-</td><td>-</td><td>-</td><td>Synonymous</td><td>1</td><td>Y</td><td>Leaky</td><td>Viner C. F1000Res. 2014;3:8-8.v2. eCollection 2014</td><td>acceptor1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>PTEN</td><td>Autosomal Dominant</td><td>NM_000314:g.89711873A>G</td><td>10</td><td>89711873</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14</td><td>5.9</td><td>-8.2</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>-1</td><td>Y</td><td>Skipping and Cryptic (retention)</td><td>Viner C. F1000Res. 2014;3:8-8.v2. eCollection 2014</td><td>acceptor-1A>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-1G>A (IVS22)</td><td>17</td><td>41199721</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.3</td><td>-0.2</td><td>-7.6</td><td>-</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA1</td><td>Autosomal Dominant</td><td>NM_007294:c.5407-1G>A (IVS22)</td><td>17</td><td>41199721</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>-12.9</td><td>1.8</td><td>14.7</td><td>-</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.517-1G>A (IVS6)</td><td>13</td><td>32900635</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>14.5</td><td>6.9</td><td>-7.6</td><td>rs81002849</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.517-1G>A (IVS6)</td><td>13</td><td>32900635</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3.3</td><td>11.4</td><td>8.1</td><td>rs81002849</td><td>-</td><td>-</td><td>Exonic</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.632-1G>C (IVS7)</td><td>13</td><td>32903579</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>7.1</td><td>-0.2</td><td>-7.3</td><td>rs81002820</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.632-1G>C (IVS7)</td><td>13</td><td>32903579</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>4.8</td><td>7.3</td><td>2.5</td><td>rs81002820</td><td>-</td><td>-</td><td>Exonic</td><td>4</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor4G>C </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.8755-1G>A (IVS21)</td><td>13</td><td>32953453</td><td>Natural</td><td>ACCEPTOR</td><td>Abolished</td><td>3.3</td><td>-4.3</td><td>-7.6</td><td>rs81002812</td><td>-</td><td>-</td><td>Intronic</td><td>0</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor0G>A </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6842G>T (p.G2281V)</td><td>13</td><td>32918695</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>5.9</td><td>3.7</td><td>-2.2</td><td>rs80358908</td><td>-</td><td>-</td><td>Missense</td><td>1</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor1G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.6842G>T (p.G2281V)</td><td>13</td><td>32918695</td><td>Cryptic</td><td>ACCEPTOR</td><td>Created</td><td>2</td><td>6.3</td><td>4.3</td><td>rs80358908</td><td>-</td><td>-</td><td>Exonic</td><td>3</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor3G>T </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7436-17T>G (IVS14)</td><td>13</td><td>32930548</td><td>Natural</td><td>ACCEPTOR</td><td>Weakened</td><td>6.4</td><td>5</td><td>-1.4</td><td>rs81002829</td><td>-</td><td>-</td><td>Intronic</td><td>-16</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-16T>G </td></tr>
<tr><td>Breast Cancer</td><td>1-5/10 000</td><td>BRCA2</td><td>Autosomal Dominant</td><td>NM_000059:c.7436-17T>G (IVS14)</td><td>13</td><td>32930548</td><td>Cryptic</td><td>ACCEPTOR</td><td>Strengthened</td><td>3.8</td><td>6</td><td>2.2</td><td>rs81002829</td><td>-</td><td>-</td><td>Intronic</td><td>-17</td><td>N</td><td>-</td><td>Mucaki EJ. Hum Mutat. 2011;32(7):735-742.</td><td>acceptor-17T>G </td></tr>
</tbody></table>

<div class="references">
<p>2. Lacroix, M., Lacaze-Buzy, L., Furio, L., Tron, E., Valari, M., Van der Wier, G., Bodemer, C., Bygum, A., Bursztejn, A.-C., Gaitanis, G., et al. (2012). Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations. J. Invest. Dermatol. 132, 575&ndash;582.</p>
<p>3. Miller, M., Stone, N.J., Ballantyne, C., Bittner, V., Criqui, M.H., Ginsberg, H.N., Goldberg, A.C., Howard, W.J., Jacobson, M.S., Kris-Etherton, P.M., et al. (2011). Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association. Circulation 123, 2292&ndash;2333.</p>
<p>6. <a target="_blank" href="http://www.health.state.mn.us/divs/cfh/topic/diseasesconds/congcataract.cfm">http://www.health.state.mn.us/divs/cfh/topic/diseasesconds/congcataract.cfm</a></p>
<p>7. <a target="_blank" href="http://www.laldeficiencysource.com/about-lal-deficiency/">http://www.laldeficiencysource.com/about-lal-deficiency/</a></p>
<p>8. <a target="_blank" href="http://www.patient.co.uk/doctor/hypertrophic-cardiomyopathy-pro">http://www.patient.co.uk/doctor/hypertrophic-cardiomyopathy-pro</a></p>
<p>9. <a target="_blank" href="http://www.patient.co.uk/doctor/dilated-cardiomyopathies">http://www.patient.co.uk/doctor/dilated-cardiomyopathies</a></p>

</div>

</body>
</html>
